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 “The most beautiful thing we can experience is the mysterious. It is the source of all true art 
and all science.” 
 
 
 Albert Einstein
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 Foreword 
 
Electricity is a fundamental force of life. It makes our heart beat, our mind think, and our 
muscles move. This thesis is about the electrochemical process that precedes 
contraction of our muscles. More specifically, it is about the speed by which an action 
potential is propagated along the membrane of a muscle fibre: the muscle fibre 
conduction velocity. 
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Introduction 
 
 
In the every day practice of the clinical neurophysiologist, muscle fibre conduction 
velocity (MFCV) is usually not given a second thought. The relevance of MFCV is 
obvious however, when one considers the origin of the motor unit potential (MUP). I will 
therefore first introduce the basic anatomy and physiology of muscle tissue, motor units 
and their potentials. Thereafter, I will discuss the generation and propagation of action 
potentials in more detail, followed by the technique that we have used to measure MFCV. 
The objectives of the thesis are integrated in the text of this introduction.  
 
I. MOTOR UNITS AND MOTOR UNIT POTENTIALS 
 
Anatomy of skeletal muscle tissue
 
Skeletal muscle tissue is build from tightly packed bundles of muscle fibres. A muscle 
fibre is a single giant cell that originates from embryonic fusion of many muscle cell stem 
cells. A fibres is a long and thin cylindrical structure, its diameter ranging from 10 to 100 
μm, and its length reaching up to 30 cm. The outer membrane is called sarcolemma, and, 
like all biological membranes, consists of a phospholipid bilayer in which proteins are 
imbedded. Inside, the muscle fibre is nearly filled with actin and myosin molecules 
running parallel to each other on the long axis of the cell. These myofilaments are almost 
perfectly aligned with each other, and lined up, the latter which is why the cell appears to 
be striated. 
    When the fibre contracts, the actin is pulled along the myosin shortening the muscle 
until the filaments are completely overlapping. Connective tissue surrounds each muscle 
fibre; another layer is wrapped around a bundle of fibres, and yet again around the entire 
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muscle. These layers of connective tissue make up the connection between individual 
muscle fibres and the tendons of the muscle, through which the force is ultimately 
delivered. Blood vessels and nerve fibres run through the connective tissue to reach the 
muscle fibres. 
    A muscle fibre needs a signal from a motor nerve to initiate contraction. Inside the 
muscle, many unmyelinated nerve twigs sprout from the nerve’s motor axon. Each twig 
lies close to the sarcolemma of a muscle fibre, in a dent that is the end-plate, or 
neuromuscular junction. Here, impulses are transmitted electrochemically from nerve to 
fibre, through the release of the neurotransmitter acetylcholin from the ending of a nerve 
twig, which then binds on receptors on the sarcolemma. 
 
Motor units
 
The cell body of an efferent motor axon is an α-motor neuron cell in the spinal cord. All 
fibres that are connected to the many nerve twigs that sprout from a motor axon, are 
therefore innervated by a solitary motor neuron. This motor neuron, its motor axon, and 
all fibres connected, together make up a motor unit. Muscles that perform fine 
movements, such as the internal muscles of the eye, usually have few muscle fibres 
connected to each motor neuron, and thus consist of many motor units. Bulky muscles 
used for large movements, such as the quadriceps muscle, can have several hundred 
muscles fibres per motor unit. The number of fibres per motor unit is a reflection of the 
amount of force that is expected to be delivered and the precision of the motor task. 
Groups of motor units usually work together to coordinate the contraction of a muscle. 
    Three types of motor units can be identified. Type I motor units are slow-twitch and 
fatigue resistant. Type II motor units are fast-twitch and easily fatigable. Intermediate 
motor units are what their name suggests. Type I motor units are generally the small 
units of a muscle, whereas type II units are the large ones.  
    The sequence of activation of motor units within a muscle is largely predetermined. 
During voluntary isometric and concentric contractions, the orderly pattern of recruitment 
is controlled by the size of the motor unit, a condition known as the size principle.21 Small 
motor units have the lowest firing threshold and are recruited first. Demands for larger 
forces are met by the recruitment of increasingly larger motor units. The largest motor 
units that contain the fast-twitch fibers have the highest threshold and are recruited last.  
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Motor unit potentials
 
The motor unit potential (MUP) is the summated electrical activity that is generated by all 
muscle fibres belonging to a particular motor unit. Because the fibres of a motor unit are 
innervated by a solitary α-motor neuron, they will all be excited almost simultaneously. As 
will be discussed in detail in the next section, muscle fibre action potentials are generated 
following neuromuscular transmission at the end-plate, and prior to contraction. 
    Electromyography (EMG) is the study of electrical activity of muscle fibres. MUPs can 
be recorded using a needle electrode, which is inserted in the muscle and positioned 
close to the muscle fibres of the active motor units. This technique is referred to as 
needle EMG (nEMG). Another way to record a MUP is to attach electrodes to the skin, 
and measure the activity from a distance, so-called surface EMG.13,44 Obviously, the 
signal that is recorded on the surface is different from that recorded close to the fibres.4,15
    Worldwide, nEMG is the golden standard in neurophysiologic examination of muscles. 
The preferred device in Europe is a so-called concentric needle electrode, which 
basically consists of two electrodes. The active electrode is tucked in the tip of the 
needle, and the large metal shaft of the needle is used as reference electrode. The 
concentric needle electrode picks up the muscle fibre action potentials that are within the 
small uptake area of the electrode: the close proximity of 0.5-2 mm in front of the 
electrode.29
    The recorded MUP represents the summation of the electrical signals of those fibres of 
a motor unit that are within the uptake area of the needle. The shape of the MUP is 
determined by two factors: the distance between the active fibres and the electrode 
(spatial factor), and the time that is needed for action potentials to travel the distance 
between the endplate and the needle electrode (temporal factor, see below). The latter 
depends on the conduction velocity of the muscle fibre, the subject of this thesis. Here, it 
becomes clear why muscle fibre conduction velocity is an important factor in routine 
EMG.  
 
II. GENERATION AND PROPAGATION OF ACTION POTENTIALS IN THE MUSCLE 
FIBRE 
 
The membrane resting potential 
 
Imagine a single cell in a compartment of extracellular fluid. Inside the cell there is a large 
concentration of positive ions, outside the cell this concentration is low, and the 
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membrane of the cell is permeable for these positive ions. The concentration gradient will 
drive ions from inside the cell out, because of the natural tendency to level off 
concentrations. This current of positive ions from intracellular to extracellular will 
establish an electrical gradient, with the inside of the cell being negatively charged. The 
electrical gradient will now force positive ions to move back into the cell to equalise 
intracellular and extracellular charges. Thus, the direction of the electrical gradient is 
opposite to that of the concentration gradient. 
    With the outward ion current, the concentration gradient will slowly decrease, while the 
electrical gradient increases. Finally, an equilibrium is reached, when the outward current 
of ions by the concentration gradient is equal to the inward current of ions by the 
electrical gradient. The difference in positive charge between outside and inside that is 
present at the equilibrium of ions currents establishes the membrane resting potential for 
this particular ion. The equilibrium or resting membrane potential can be calculated for 
any ion with the so-called Nernst equation (e.g. for potassium): 
i
e
K K
K
E
][
][
ln4.61 +
+
=+  
[K+]e is the extracellular concentration, and [K
+]i is the intracellular concentration.  
    In human cells, EK+ is -95 mV, ENa+ is +60 mV, and ECl- is – 80 mV. All cells in the 
human body tend to a resting potential across the cell’s membrane. It is the result of 
concentration and electrical gradients from the ions inside and outside the cell, and the 
differences in permeability of the membrane for different ions. Inside cells, the highest 
concentration is that of potassium (K+), outside it is sodium (Na+). Most anions inside are 
organic molecules, such as carbohydrates, while outside it is chloride (Cl-). The resting 
potential (Vm) is now the result of equilibrium potentials of the major ions: EK+, ENa+ and 
ECl- . It is expressed by the Goldman equation, which resembles the Nernst equation, but 
now for multiple ions, each weighed by its permeability through the membrane: 
2
1ln4.61
C
CVm =  where 
  1 ][][][ iKeKeK ClPNaPKPC
+++
+++ ++=  and 
eKiKiK ClPNaPKPC ][][][2
+++
+++ ++= ,  
where Px is permeability coefficient for ion x.. 
    These values lead  for human skeletal muscle fibres to Vm  being about -70 mV.  
    The lipid bilayer of the sarcolemma has a high electric resistance. It is virtually 
impermeable to ions, which are only permitted to flow through special channels in the 
sarcolemma. The lipid bilayer is responsible for the membrane capacitance. Capacitance 
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is the ability to offset ion charges by interacting on a distance with charges present on the 
other side of the membrane. It therefore acts as a buffer for charge. Imbedded in the 
sarcolemma, proteins form aqueous pores or ion channels through which certain ions 
can cross the membrane. These ion channels regulate membrane resistance (Rm), and 
the ion conductance of the membrane. 
    The -70 mV sarcolemmal resting potential of human skeletal muscle fibres is almost 
equal to the equilibrium potential of Cl-, but less negative than EK+, and less positive than 
ENa+. Thus, an outward K
+ current and an inward Na+ current will be present, according to 
their respective concentration and electrical gradients. The efflux of K+ ions is the most 
important reason why the inside of the cell is charged -70 mV. 
    A stable resting potential implies that the charge of the inward current must be equal to 
that of the outward current. However, the sarcolemma is 50-100 fold more permeable for 
K+ than it is for Na+.1 This is compensated for by the much larger difference between ENa+  
and Vm, which will cause the Na
+-influx to be similar to the K+-efflux despite the low PNa
+, 
as compared to the relatively smaller difference between EK
+ and Vm and the much 
higher PK
+. 
    Thus, an electrical equilibrium is achieved. However, the continuous flow of ions will 
reduce the concentration gradient and eventually the ion currents will stop. To avoid this, 
the cell actively maintains the concentration gradient by pumping Na+ out and K+ ions 
back in the cell. This is done by the sarcolemmal ATP-dependent Na+-K+ exchange 
pump. 
 
Action potential generation 
 
Action potentials are transient, all-or-none voltage impulses that are generated by 
neurons to transmit information, and by muscle fibres to initiate contraction. A crucial 
feature of action potentials is that they are propagated: action potentials are continuously 
regenerated along the length of the fibre, in such a way that there is no decrement in the 
strength of the potential regardless of the length of the fibre. Before I describe how this is 
achieved, action potential generation needs to be explained. 
    If a small amount of current is injected into a squid giant axon, the voltage across the 
membrane changes in accord with the current’s polarity and strength, and with Rm and 
the membrane’s capacitance. Thus, the injection of positive current will depolarise 
(towards 0 V) the sarcolemma, whereas negative current will hyperpolarise (make more 
negative) the membrane. However, below a certain level of depolarisation, the 
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sarcolemma undergoes an explosive change. This level is called the ‘threshold’ and it is 
from this moment that the action potential is generated at this point. 
    The major change in the first phase of action potential generation is a massive 
increase of Na+ conductance of the sarcolemma. This is the result of the opening of 
sarcolemmal Na+ channels within a fraction of a millisecond. These channels are 
‘voltage-gated’: their state (open or closed) depends on the voltage across the 
sarcolemma. This is mediated by proteins which change their shape depending on the 
voltage, and as such act as gates. The sodium channel has an outer and an inner gate 
which operate independently. Upon depolarisation, the outer gate, which is closed at Vm, 
opens to allow Na+ influx, but the inner gate, which is open at Vm, slowly closes to 
terminate the influx within a few milliseconds. 
    Initially, the influx of Na+ ions increases about 50 fold, and soon exceeds the efflux of 
K+ ions. Thus, the inside of the cell will continue to depolarise and even faster, towards 
ENa+. The peak of Na
+ conductance is reached after about 1 ms, before the sodium 
channel inner gates closes. Meanwhile, depolarisation has increased potassium 
conductance as well, up to 20 fold. The K+ channel is also a  voltage-gated channel, but 
less complicated: it has only one gate which is closed at -100 mV, and gradually opens 
towards depolarisation. These gates are slower, and take about 1 ms to respond to a 
voltage change. 
    The increasing K+ efflux in the second phase of action potential generation will 
counteract the Na+ influx, and eventually the membrane potential returns to its normal 
resting value. Approximately 3 ms have passed from depolarisation below threshold to 
return to resting state. The sarcolemma will be unable to generate another action 
potential (refractory period), for as long as the sodium channel inner gates are closed (∼ 
1.5 ms). The time course of the action potential and the underlying Na+ and K+ 
conductances in a nerve fibre are shown in Figure 1. 
    Much of the work elucidating the basic properties of the action potential and the 
underlying conductances, as described in the above, was carried out in the late 1940s 
and early 1950s on giant axons of the squid by two English scientists, Alan Hodgkin and 
Andrew Huxley. The Hodgkin-Huxley mathematical equations that were published in 
1952 reconstruct the entire course of the action potential almost perfectly.23 Noticably, 
they postulated this channel concept without having ever seen an ion channel, let alone 
specific ones. They were, together with sir John Eccles, awarded the Nobel Prize for 
medicine in 1963 for this and other contributions.  
    The time course of intracellularly recorded action potential from a muscle fibre differs 
essentially from that of an unmyelinated nerve fibre. The initial phase of depolarisation 
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and repolarisation is similar, but repolarisation is incomplete. Unlike a nerve, an 
additional 30 ms is required for restitution of the resting membrane potential. There is no 
phase of hyperpolarisation, as in the axon.10
 
    The depolarisation threshold for muscle fibres is 15-30 mV, partly depending on the 
membrane’s resistance and capacitance. There are several ways to depolarise a muscle 
fibre below threshold, and initiate action potential generation. 
 
FIGURE 1. 
(top) Time course of an 
action potential of a 
nerve fibre (Vm, solid 
line). Sodium and 
potassium 
conductances (GNa and 
GK) are represented by 
dashed lines. 
(bottom) The state of 
the ion channels during 
the time course of the 
action potential. A, 
resting state; B, 
depolarisation; C, 
repolarisation; D, 
overshoot. The m-gate 
is  the outer gate of the 
sodium channel, and 
the h-gate is the inner 
gate of the channel. 
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    Physiologically, communication between nerve twig and muscle fibre is achieved 
electrochemically by the transmission of acetylcholine in the neuromuscular junction. The 
binding of acetylcholine on the sarcolemmal external receptors triggers a change in the 
shape of intracellular proteins which are connected to the receptors. The intracellular 
proteins are also connected to nearby Na+ channels, and their shapeshift triggers the 
opening of those Na+ channels, resulting in Na+ influx, and ultimately leading to 
depolarisation below threshold. 
    As such, initial depolarisation needed to generate an action potential is induced by a 
chemical reaction of sarcolemmal proteins. From here on, the action potential is 
propagated as described in the next paragraph. 
    Another way to evoke action potentials is to modify the extracellular charge. As said, 
the outside is positively charged due to the K+ efflux. By inducing a negative extracellular 
current, the difference between the extracellular and intracellular charge is reduced. This 
will depolarise the membrane, and, if below threshold, open the sodium channels to 
initiate action potential generation. This principle is used in neurography, where whole 
nerve bundles are stimulated by electrical currents through electrodes at the skin. It can 
also be applied to muscle fibres. 
    Finally, a positive charge can be injected into an isolated muscle fibre using pipet 
electrodes in an in vitro environment. This technique is used in patch-clamp experiments, 
in which the membrane potentials can be measured very precisely in response to 
different stimuli and conditions. For example, individual ion channels can be studied 
using this technique. 
 
Action potential propagation
 
The action potential is the result of local changes of the membrane potential, induced by 
small ion currents through voltage-gated sarcolemmal channels. As said, a primary 
attribute of action potentials is that they are propagating. Why is the large potential 
change at the site of the impulse activation of a fibre not enough to depolarise the entire 
fibre, similar to a current in a long electrical cable, which when induced on one end, 
initiates an almost equal potential change on the other end? To understand why action 
potential propagation is essential, the spread of current down the fibre must be 
considered. 
    At the site of the potential change, a small local current will flow along the path of the 
least resistance. The Rm is much higher than the cytoplasmic resistance of the fibre (Ri); 
thus most of the current will flow down the fibre. Nevertheless, a small amount of current 
1. Introduction 20 
will escape across the membrane and reduce the amount of current flowing down the 
fibre. As the amount of current decreases, the potential difference across the 
sarcolemma declines. 
    Rm is determined by the sarcolemmal properties, such as the number of channels in 
the membrane, and whether these are open or closed. The Ri relates mainly to the size 
of the fibre; the larger the fibre, the lower is the Ri. Therefore, an interplay between Rm 
and Ri determines how far current spreads down a fibre and how great the voltage will be 
across the sarcolemma. The decline of voltage as a function of fibre length can be 
expressed as the length constant (λ). Noticably, a bigger muscle fibre will have a lower 
Rm, but also a larger sarcolemmal area and therefore more channels.  
    Regardless of how one manipulates Rm and Ri, the voltage across the sarcolemma 
decays substantially within just a few millimetres of where the action potential is 
generated. In order to maintain the strength of the action potential, so that it can be 
propagated along the whole fibre, a new action potential is generated along the way. The 
Na+ ions that flow down the fibre during action potential generation, establish a small 
local current of positive ions. This will depolarise the membrane adjacent to the site of the 
action potential. If the local current is strong enough to depolarise the membrane to 
below threshold, a next action potential will be generated, adjacent to the previous one. 
This process is repeated, until the end of the fibre is reached. 
    There are two mechanisms that will prevent propagation of the action potential back to 
where it came from. First, the Na+ channels may be refractory due to the closed inner 
gates, which will not open before the sarcolemma is repolarised to a certain level. 
Second, K+ conductance is increased after the generation of an action potential. If K+ can 
leave more easily, more Na+ must enter the cell to initiate an action potential. 
Additionally, Cl- ions have a stabilising effect in a similar way as K+ ions. Thus, the 
threshold for action potential generation is elevated. 
    The nature of propagation implies that once action potential generation is initiated, it 
will propagate along the entire length of the fibre. This is the ‘all-or-none principle’ of 
muscle fibre and nerve fibre excitation. In normal conditions, a muscle fibre is either in a 
resting state, or excited. 
    The life cycle of an action potential during its run along the sarcolemma can be 
illustrated by the so-called ‘moving quadripole’ model (Figure 2). The quadripole consists 
of two adjacent action potentials, with a positive outer pole as the leading local current of 
sodium ions. Two of these quadripoles will move, starting at the endplate, to either side 
of the tendons, where they fade out. 
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Calcium ions and muscle fibre action potentials 
 
Calcium ion concentration also contributes to action potential generation and 
propagation. A Ca2+ gradient of 1:10,000 is maintained by the sarcolemmal Ca2+ pump, 
which pumps Ca2+ from intracellular into the sarcoplasmatic reticulum, or to extracellular. 
The extracellular Ca2+ concentration co-determines the speed with which the voltage-
gated sodium channels open, the lower the faster. If extracellular Ca2+ concentration is 
less than 50% of normal, the sodium channels may even open spontaneously. 
    Furthermore, voltage-gated Ca2+-Na+ channels are present. These are permeable for 
Ca2+ and for Na+ ions. The activation of these channels in response to voltage changes is 
10-20 fold slower than the activation speed of voltage-gated Na+ channels. For this 
reason, these channels are referred to as ‘slow channels’. The slow kinetics cause a 
plateau phase in the action potential that lasts 2-3 ms. The contribution of Ca2+-Na+ 
channels to the generation and propagation of action potentials is relatively small in 
skeletal muscle tissue, but important in, for instance, cardiac muscle tissue. 
 
 
 
FIGURE 2. The ‘moving quadripole’ model of propagated action potentials, starting from the 
endplate and ending at the tendons: (A) initiation phase, (B) propagation phase, (C) 
termination phase 
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Action potentials lead to contraction 
 
Action potentials are propagating not only along the sarcolemma of the fibre, but also into 
the fibre’s inner system, the t-tubuli. This is a system of sarcolemmal extensions, which 
penetrate the fibre transversally. They are closely related to an extensive system of 
cisterns running in a longitudinal direction, next to the myofilaments, called the 
sarcoplasmatic reticulum. The t-tubuli facilitate transmission of the sarcolemmal action 
potential to the membrane of the sarcoplasmatic reticulum. It is unclear whether this is 
achieved by passive electrical spread of depolarisation, or by propagation through the t-
tubuli themselves. In any case, it results in local depolarisation of the membrane of the 
sarcoplasmatic reticulum. 
    The sarcoplasmatic reticulum holds a large supply of Ca2+ ions. Following 
depolarisation of the membrane, Ca2+ ions are released in large quantities into the 
intracellular space. Ca2+ ions are essential components in the process of cross-bridging 
of actine and myosin molecules, leading to contraction. When released intracellular, they 
bind to troponin. This molecule is intertwined with actine and tropomyosin, forming thin 
filaments. Troponin acts as a repressor molecule: actine can interact with myosin to form 
cross-bridges only if Ca2+ is bound to troponin. If unbound, the interaction is blocked by 
troponin. Thus, contraction of a muscle fibre depends strongly on the intracellular Ca2+ 
concentration. 
    A tetanic contraction is the result of a continuous high intracellular Ca2+ concentration. 
This can occur when the next action potential has arrived before enough intracellular 
Ca2+ has actively been pumped back into the sarcoplasmatic reticulum for the repressor 
molecules to take effect. In this circumstance, the intracellular Ca2+ concentration will 
gradually increase. As a result, the force generated by the contraction will increase as 
well. 
 
III. MUSCLE FIBRE CONDUCTION VELOCITY – INVASIVE MEASUREMENTS 
 
The speed of action potential propagation along the sarcolemma can be measured, and 
expressed as conduction velocity (MFCV) in meters per second. There are several 
techniques available to measure MFCV.3 Some measure MFCV close to the source, with 
needles inserted into the muscle, much like nEMG. Other techniques use surface 
electrodes attached to the skin, far away from the source. The electrical activity, when 
recorded at the skin, is conducted and spatially and temporally filtered through various 
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layers of tissue. Again, the effect of volume conduction must be taken into account when 
interpreting these recordings.4,15
    It should also be noted that the term MFCV is somewhat misleading when referred to a 
measurement on the skin surface. The actual recording is that of conduction velocity of 
multiple muscle fibres within a motor units, instead of individual muscle fibres. Surface 
measured MFCV therefore reflects the averaged conduction velocity of the muscle fibres 
of that unit. Due to various reasons, MFCV measured on the surface from motor units 
during voluntary contraction, is about 1,0 m/s higher on average and less variable than 
MFCV measured with needles near the fibres.43
    This thesis is about invasive measurements, using needle electrodes inserted in the 
muscle and close to the active muscle fibres. I will therefore not elaborate any further on 
measurements made superficially. 
 
History 
 
Measuring the propagation velocity of action potentials of single muscle fibres with 
needles was first described by Buchthal in 1955,5 aiming to improve his measurements of 
motor unit conduction velocities. He stimulated muscle fibres in the brachial biceps 
muscle using a bipolar needle electrode. MFCV was estimated by measuring the delay 
between responses obtained from several concentric needle electrodes at distance of 15-
35 mm to the stimulating electrode. He measured a mean MFCV of 4.02 m/s ± 0.13 
(standard deviation (SD)) in 10 healthy adults. 
    In 1966, Eric Stålberg wrote his PhD-thesis on intramuscular measurements of 
propagation velocities, both during voluntary contraction, and electrical stimulation of 
muscle fibres.33 He used a bipolar needle electrode to stimulate the fibres, and a multi-
electrode needle with 14 leads to record, which he had developed with Ekstedt. He found 
a mean MFCV of 3.7 m/s ± 0.7 (SD) in 12 healthy adults. However, he suggested that at 
lower currents of shorter duration, nerve twigs were in fact stimulated more than muscle 
fibres directly. Only stimuli of longer duration and higher voltage could directly evoke 
muscle fibre potentials in curarised rabbit muscle. This led him to believe that direct 
measurements of MFCV could not be made without errors induced by nerve twig 
stimulation. 
    Hopf reported measurements of electrically activated fibres of the brachial biceps 
using two monopolar needles for stimulation and two steel needles for recording.24 The 
method, and his results, published in 1974, were similar to those of Buchthal.  
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The ‘Troni’ method 
 
The techniques described thus far were cumbersome, involving 3 or 4 needles, which 
had to be placed in such a way that the same fibre was measured by all of them at 
different sites in the muscle. Moreover, there was doubt about the origin of the MFCVs 
that were measured, as said. For many years, little scientific work was done on the 
subject, and MFCV measurements were not applicable in a clinical setting.  
    This changed when Troni introduced a technique that overcame the two major 
problems.34 He stimulated muscle fibres in the brachial biceps at a distal point near the 
tendon, far away from the nerve twigs in the endplate-zone, which is well defined in the 
middle part of this muscle. Two Teflon coated monopolar needles exposed at the tip were 
used for stimulation electrodes. For recording purposes, a single fibre needle electrode 
was inserted 50 mm proximally, guided by a palpable twitch of the contracting fibres. He 
was able to identify single muscle fibre potentials, individually distinguishable in a 
complex of many, because of different MFCV values. He demonstrated that his 
recordings represented direct muscle fibre responses, as they remained present when 
the neuromuscular junction was curarised. Moreover, he found a linear relation between 
MFCV and different distances between stimulating and recording electrodes, indicating 
that fibres were stimulated near the tip of the Teflon coated needle. Much like Stålberg, 
he occasionally measured other components, which he ascribed to nerve twig 
stimulation. These were usually preceeding the complex of muscle fibre potentials, and 
could be easily identified by an accompanying visible muscle twitch. When the current 
was lowered, or the stimulation electrodes moved, these responses changed or 
disappeared, but not in an all-or-none fashion that is typical for direct muscle fibre 
responses. With this in mind, Troni’s technique proved to be a reliable and easy way to 
measure MFCV invasively. 
    This technique has been used by others, with some variations. Normal values that 
have been reported are listed in Table 1. 
    A conduction velocity histogram can be compiled from all fibres measured. Figure 3 
shows the histogram from the data of normal subjects that Troni published. The 
distribution was Gaussian, there was no indication of a bimodal distribution. Such a 
bimodal distribution may be considered, as conduction velocity depends on fibre 
diameter, and type I and type II fibres have different mean diameters. 
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TABLE 1. Overview of measurements of MFCV in healthy subjects from the literature. 
First author, year of 
publication 
Site1 Stimulus 
electrodes2
Subjects3 Mean MFCV ± 
SD (m/s) 
Range MFCV 
(m/s) 
Buchthal, 1955 BB BP 10 V 4.02 ± 0.13 3.3 – 5.2 
(means) 
Stålberg, 1966 BB BP 12 V 3.7 ± 0.7  
 EDC BP 7 V 3.15 ± 0.75  
 RF BP 2 V 3.39 ± 0.68  
 FR BP 2 V 2.01 ± 0.39  
Hopf, 1974 BB NN 16 (11M / 5F) 
fast twitch fibers 
slow twitch fibers 
3.92 ± 0.09 
4.14 ± 0.58 
3.75 ± 0.31 
 
Gruener, 1979 IC  V 3.9 ? – 5.1 
Troni, 1983 BB NN 25 M 3.81 ± 0.34 2.5 – 5.2 
   25 F 3.42 ± 0.33 2.3 – 4.5 
Chino, 1984 BB NN 13 V 5.10 ± 0.80  
Cruz Martinez, 1989 BB 
 
VM 
NN 
 
NN 
13 M 
17 F 
19 M + 1 F 
3.55 ± 0.53 
3.48 ± 0.25 
3.49 ± 0.32 
1.46 – 5.05 
 
1.37-5.34 
Cruz Martinez, 1989 BB NN Infants 3.24 ± 0.53 1.81 – 5.00 
Van der Hoeven, 1993 BR NS 4 M 3.37 ± 0.47 2.98 – 4.00 
Van der Hoeven, 1995 BB NS 30 M 3.25 ± 0.21  
   21 F 3.07 ± 0.21  
Van der Hoeven, 1995 DT NS 3 M 3.36 ± 0.53  
Van der Hoeven, 1995 GC NS 3 M 3.76 ± 0.46  
Van der Hoeven, 1995 TA NS 3 M 3.43 ± 0.37  
Gutierezz, 1996 BB NS 25 young 
25 old 
5.7 ± 0.5 
4.5 ± 0.4 
 
Naumann, 1996 RF NN 10 V  4.00 (median 
fastest) 
Mitrovic, 1999 BB NN 10 M 3.15 ± 0.63  
Vogt, 2006 BB NN 24 V 3.36 ± 0.2 2.5 – 4.3 
(means) 
1: BB, m.biceps brachialis; BR, m.brachioradialis; DT, m.deltoideus; EDC, m.extensor digitorum 
communis; FR, m.frontalis; GC, m.gastrocnemius; IC, intracellular; RF, m.rectus femoris; TA, m.tibialis 
anterior; VM, m.vastus medialis. 
2: BP, bipolar needle electrode; NN, two needle electrodes; NS, needle and surface electrode. 
3: F, female; M, male; V, volunteer. 
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FIGURE 3. Histogram of 
conduction velocities 
from 50 healthy 
volunteers (25 females 
and 25 males). Mean 
MFCV was significantly 
different between males 
and females, and a clear 
Gaussian distribution in 
both groups was found. 
Adapted from Troni et al. 
(1983). 
 
 
 
The modified Troni method 
 
To further simplify the technique, several modifications were made, tested, and approved 
for.37 One of the stimulation electrodes, the anode, could be replaced with a silver 
surface electrode, without affecting the very local stimulus field at the needle tip of the 
cathode. Furthermore, the duration of the stimulus was reduced, from the original 0.2 ms 
to 0.05 ms. This reduced the chance of simultaneously stimulating nerve twigs, contrary 
to Stålberg’s believe. Finally, the recording single fibre electrode was replaced with a 
concentric needle electrode. This electrode has a larger window of view, which makes it 
easier to find the fibre potentials, without losing any relevant discriminative power. 
 
Factors influencing on conduction velocity
 
Fibre diameter is the main determinant of MFCV. As said before, both Ri and the 
membrane’s conductivity are determined by the diameter of the fibre. A linear correlation 
between fibre circumference and propagation velocity is assumed, based on the core 
conductor model.6,25 Håkansson demonstrated a linear relation, measured in isolated 
fibres of frog muscle.18 A correlation between cross-section area and fast fibre conduction 
velocities was found in the human vastus lateralis muscle.14 However, it has yet to be 
determined that a linear correlation between fibre diameter and propagation velocity 
actually holds true in human muscle fibres in vivo. 
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    Nandedkar and Stålberg have presented a relatively simplified equation to calculate 
propagation velocity.29 In their model, the muscle fibre is assumed to be straight and 
cylindrical in a medium with cylindrical anisotropy. They used Stålberg’s normal values 
for MFCV (3.7 m/s ± 0.71), normal values for fibre diameters obtained from literature (25-
85 µm), and assumed a linear relation: 
 
V (m/s) = 2.2 + 0.05*(d [µm] - 25). 
 
It is conceivable that this indirectly determined linear relationship between propagation 
velocity and diameter is not always valid, particularly not in pathological conditions. Other 
factors may contribute to an altered resting potential and propagation, such as 
dysfunctional sarcolemmal ion channels, or loss of integrity of the phospholipid bilayer. 
 
    A difference of MFCV between male and female subjects was found by several 
authors (Table 1, Figure 3), but it was not always statistically significant. It was attributed 
to slightly lower fibre diameters of females as compared to males.  
    The effect of age has also been studied. Lower MFCV was found in elderly persons, 
although not significant in another report.17,41 Similar to the difference between sexes, it 
was attributed to generalised fibre atrophy that can be seen in the elderly (sarcopenia).  
    Fibre length is not static, but changes during each contraction. Fibre length also 
depends on the position of the joint, and on the type of contraction (isometric or isotonic). 
There have been conflicting reports on the relation between fibre length and MFCV. 
Unchanged MFCV was found in isolated frog muscle fibres during stretch by up to 
150%.19,22,26 Increasing MFCV was found in human fibres with increasing length, both 
with invasive measurements and superficial measurements.2,36 However, others have 
reported the opposite: short fibres have a lower threshold-value, are easier excitable, and 
have a higher propagation velocity.12 In fibres with a length less than two times the length 
constant λ, the membrane fired practically simultaneously. It has also been suggested 
that type I fibres adapt differently to fibre stretch than do type II fibres.42
    The firing rate, the rate by which new action potentials are generated, is also of 
importance. Two mechanisms related to the firing rate have been described: the 
conduction velocity recovery function, and long-lasting supernormal conductivity during 
and after exercise.27,39
    The MFCV recovery function describes the changes in MFCV particularly in the first 
100 ms after an action potential has been generated. Following an action potential and a 
short refractory period, the sarcolemma enters a period of supernormal conductivity, in 
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which action potentials are propagated with a speed of up to 120% of normal. It is an 
important mechanism, because muscle fibres fire repetitively at high rate during voluntary 
contraction, at frequencies ranging from 5 to 40 Hz. The induced supernormal 
conductivity facilitates propagation in the muscle fibres during contraction. 
    A supernormal conduction velocity of up to 20% was reported following 1 minute of 
maximal voluntary contraction, and following intermittent isometric contractions at 50% of 
maximum force.38,39 This supernormal conductivity could last for more than an hour, 
indicating that this adaptation is of a different order than the supernormal conduction 
resulting from the MFCV recovery curve. It was attributed to a combination of altered 
membrane properties, muscle fibre swelling, and temperature increase. At higher force 
levels however, MFCV decreased. This was attributed to local ischemic changes that 
occur during contractions at higher force levels. 
    The issue of fatigue is subject of much research, most of which is done with MFCV 
measured with surface EMG. MFCV decrement of up to 70% during sustained 
contraction has been reported, and MFCV decrement of 20% after 1 minute of maximal 
contraction.20,39 Recovery to initial values was significantly slower in elderly subjects as 
compared to young subjects. Although suggested to be present, a clear distinction 
between type I and type II muscle fibres with respect to MFCV changes in fatigue has not 
been reported.42
    The effect of temperature on MFCV has not been investigated extensively. 
Temperature affects biological kinetics in a general fashion. For example, ion channels 
open and close slower in cold. This may be an explanation for the slowing of 0.1-0.2 m/s 
per °C that has been reported.33 Others have reported a linear decay of 0.13 m/s per °C, 
and 0.05 m/s per °C in amphibian muscle.31,32
 
    It can be concluded that many questions concerning propagation of action potentials 
along the sarcolemma of human muscle fibres in vivo remained unanswered. The first 
part of this thesis will address some of the issues. 
 
 
OBJECTIVE 1 
 
To study significant determinants of MFCV in human muscle fibres in 
vivo. 
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IV. MUSCLE FIBRE CONDUCTION VELOCITY STUDIES – TECHNIQUE AND NORMAL 
VALUES 
 
Figure 4 shows the standard setup of invasive MFCV measurements that we use in our 
laboratory. It is referred to as the ´modified Troni method´, and it is this method that we 
have used in the experiments described in this thesis. 
 
    
 
FIGURE 4. Setup of the ‘modified’ Troni method. See text for a detailed description. 
 
 
    The following parameters are used: stimulus duration: 0.05 ms, stimulus strength: 
varying between 2-15 mA depending on the response, and stimulus rate: 1 Hz. Filter 
settings for recording: 500 Hz high pass and 10 kHz low pass filter. 
    During a measurement, the subject lies comfortably, while the muscle that is to be 
investigated remains in a relaxed state, at 10-20º flexion. The stimulation needle 
electrode is inserted in the distal part in the muscle, just proximal from the tendon. The 
surface electrode is placed on the skin above the tendon. Current is then induced with 
increasing strength, until a small but visible movement of the stimulus electrode is seen. 
A visible muscle twitch may be indicative of nerve twig stimulation and should be 
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avoided, either by lowering the current, or by displacing one of the stimulus electrodes, 
until the twitch is gone. 
    A concentric needle electrode is then inserted 50 mm away, measured at the skin, 
proximal to the stimulus needle electrode. As guidance, the contracting bundle of muscle 
fibres can be identified by touch, much like a pulsating artery. The concentric needle is 
manipulated until a complex of sharp spikes is identified. 
    In each measurement, 5 sequential recordings are taken at a 1 Hz stimulus frequency. 
Those spikes that are reproducible in all sequential recordings are considered to be 
muscle fibre potentials, evoked by  direct  muscle  fibre  stimulation,  rather than  
voluntary  contraction,  or spontaneous  muscle fibre discharges. An example of a 
measurement is given in Figure 5, in which 5 sequential traces of recording are 
superimposed, and very little variation is present. 
    A test should have recordings of at least 20 individual muscle fibre potentials, each 
exceeding 20 microvolt in amplitude. Spike latency is measured to the positive peak. 
Conduction velocity is calculated using the distance between stimulating and recording 
electrode, measured at the skin. This introduces a potential error, if the needles are not 
inserted perpendicularly to the muscles, or if the muscle fibres run skew. This error can 
be up to 7%.37 
    The velocities of all spikes recorded are used to calculate mean MFCV, and the ratio 
between the fastest and slowest fibre (F/S ratio). Mean MFCV and F/S ratio are the 
primary outcome measures of a test. A test usually takes about 15 minutes to complete. 
 
 
Figure 5. Example of a recording of 
multiple muscle spikes, using the 
‘modified’ Troni method. In this 
figure, 5 superimposed recordings 
are seen.  
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    Our normal values were obtained from 39 healthy volunteers: 20 females (mean age 
30 years, range 19-57 years), and 19 males (mean age 30 years, range 20-44). Mean 
MFCV for the whole group was 3.6 m/s, SD 0.4 m/s. F/S ratio was 1.5, SD 0.3. 
Conduction velocities that we found in the whole control population ranged from 1.9 to 
6.4 m/s. 
    We did not find a significant difference between mean MFCV of female subjects (3.6 
m/s) and male subjects (3.7 m/s). Therefore, our normal values are applicable to both 
sexes. We use 2.8 m/s (mean minus 2 SD) as lower limit for mean MFCV, and 2.1 as 
upper limit for F/S ratio (mean plus 2 SD). Disregarding the lack of sex differences, our 
normal values are in accordance with those found by Troni, but slightly higher than those 
found by Cruz-Martinez, and van der Hoeven.8,34,37
 
V. MUSCLE FIBRE CONDUCTION VELOCITY STUDIES AS A DIAGNOSTIC TOOL 
 
There have been a several studies that have reported abnormal MFCV findings in 
patients with various neuromuscular diseases. Most of these studies were retrospective 
of nature. Moreover, selected groups of patients with a clear-cut disorder were compared 
to healthy controls. Although these studies do provide information on the abnormalities of 
MFCV that can be found in those disorders, they cannot be used to assess the diagnostic 
value of MFCV measurements. 
    The results of the studies that have been published are presented in Table 2. Slowing 
of conduction velocity was found both in myopathic and neurogenic disorders. The range 
of conduction velocities was often increased in patients. 
    The findings were however non-specific. Slowing of propagation was found in many 
disorders with different underlying pathology. Fibre diameter, the main determinant of 
MFCV, is abnormal in most myopathies and neurogenic disorders. In myopathies, the 
amount of fibre atrophy can be minimal or severe, and fibre hypertrophy may be present, 
for example in dystrophic myopathies. In neurogenic disease, a bimodal distribution of 
diameters may be present, with atrophic denervated fibres on one hand, and 
normotrophic or hypertrophic reinnervated fibres on the other. However, it has not proven 
to be possible to make a distinction between neurogenic disorders and myopathies, 
based on MFCV results alone. 
    Furthermore, the established neurophysiologic technique, which is nEMG, is excellent 
in distinguishing neurogenic from myopathic disorders. For this reason, MFCV studies 
were not thought to be of additional discriminating value. However, a study that 
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compared nEMG and MFCV in the diagnosis of myopathies and neurogenic disorders, 
has not been performed yet. 
   This leads to the second objective of this thesis.  
 
 
 
 
 
OBJECTIVE 2 
 
To determine the diagnostic value of MFCV studies in neuromuscular 
disorders 
 
 
VI. OUTLINE OF THE THESIS 
 
Following the introduction, part 1 of the thesis will address the first objective. Some 
experiments concerning physiological determinants of MFCV will be presented. The 
second part of the thesis concerns the clinical application of MFCV studies. The results of 
MFCV measurements in various myopathic and neurogenic disorders will be presented, 
and the diagnostic value of the technique will be discussed. Hereafter, a summary of the 
findings will be given, including a short discussion of the technique. 
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TABLE 2. Overview of MFCV studies in neuromuscular patients. 
First author, 
year of 
publication 
Site1 Disorder3 Sub-
jects 
Mean MFCV ± 
SD (m/s) 
Ratio fastest 
to slowest 
MFCV 
Range 
MFCV 
(m/s) 
Troni, 1983 BB HOPP 6 2.33 ± 0.51 to 
3.08 ± 0.44 
  
Chino, 1984 BB PMD 4 4.69 ± 0.43   
 BB Polymyositis  6 4.27 ± 0.71   
Van der 
Hoeven, 1993 
BB Plexus, no 
reinnervation 
10 1.83 ± 0.52 2.32 ± 0.76  
  Plexus, after 
reinnervation 
14 1.96 ± 0.32 4.36 ± 1.36  
  Amyotrophic 
lateral sclerosis 
22 2.84 ± 0.38 3.26 ± 0.92  
Cruz Martinez, 
1990 
BB Duchenne 
children 
14 2.38 ± 0.94  0.45 – 5.29 
Cruz Martinez, 
1997 
BB HOPP 6 2.79 ± 0.23  2.25 – 5.00 
Cruz Martinez, 
1999 
BB Denervation and 
reinnervation 
12 2.02 ± 0.44 2.21 ± 0.10  
 VM Disuse atrophy 21 2.81 ± 0.66 2.34 ± 1.17  
Vogt, 2006 BB Myopathy 8 2.86 ± 0.25  1.4 – 4.0 
(means) 
 BB Neurogenic 9 3.06 ± 0.34  1.6 – 4.8 
(means) 
1: BB, m.biceps brachii; VM, m.vastus medialis 
2: NN, two needle electrodes; NS, needle and surface electrode 
3: HOPP, hypokalemic periodic paralysis; PMD, progressive muscular dystrophy 
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ABSTRACT 
 
To determine the relation between muscle fiber conduction velocity (MFCV) and muscle 
fiber diameter (MFD) in pathological conditions, we correlated invasively measured 
MFCV values with MFD data obtained from muscle needle biopsies, in ninety-six patients 
with various neuromuscular disorders. MFCV was significantly correlated with MFD and 
independent of the underlying disorder. Pathological diameter changes were fiber type 
dependent, with corresponding MFCVs. A linear equation is well expressing the relation: 
MFCV (m/s) = 0.043*MFD (μm) + 0.83. We conclude that fiber diameter determines 
MFCV largely , independent of the underlying neuromuscular disorders studied.  
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INTRODUCTION 
 
The propagation velocity of action potentials along nerve and muscle fibers increases 
with increasing fiber diameter. In frog muscle, a linear relationship between muscle fiber 
diameter (MFD) and muscle fiber conduction velocity (MFCV) was found by Håkansson.5 
For healthy human muscle fibers, the relationship between MFCV and MFD was 
estimated from (separate) literature data on fiber diameters and velocities  as MFCV 
(m/s) = 0.05*MFD (μm) + 0.95.8 In various neuromuscular disorders MFCV is 
abnormal1,3,14 which is generally ascribed to an increased MFD variability,10 although 
sarcolemmal lesions and fiber splitting may also influence MFCV.4 To date, no studies on 
the intrasubject relation between MFCV and MFD in either individual patients or healthy 
subjects are available. 
    The aim of the present study was to determine how MFCV and MFD are related in 
subjects with various neuromuscular diseases, possibly dependent on the 
pathophysiological characteristics of the disease. A dependence on (a specific) disease 
is a starting point for further investigating underlying causes, whereas invariance would 
yield a method for predicting fiber size from MFCV measurements in neuromuscular 
patients and in muscle waste, e.g. in the elderly. 
 
METHODS 
 
Subjects 
Patients with a clinical indication for a muscle biopsy were asked to participate in this 
study. All subjects were seen by a neurologist with neuromuscular expertise within the 
Neuromuscular Centre Nijmegen before inclusion. After providing their informed consent, 
they underwent a routine diagnostic work-up, including laboratory investigation, routine 
electromyography (EMG), and muscle biopsy. The final diagnosis, made by the 
neurologist, was based on the clinical findings and the results of the diagnostic work-up. 
Three disease subgroups were defined, namely various non-inflammatory myopathies, 
inflammatory myopathies, and neurogenic diseases. The study was approved by the 
University Hospital’s ethic committee, and in adherence with the principles of the 
Declaration of Helsinki. 
    The generally preferred site for MFCV measurements was the brachial biceps muscle, 
for the biopsy it was the quadriceps muscle. For the purpose of the study, the MFCV 
measurements and the biopsy study were performed in the same affected muscle 
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(brachial biceps or quadriceps muscle) when clinical symptoms were significantly 
different between the proximal leg and the arm muscles. 
  
Measurement of MFCV 
MFCV was measured according to the modified Troni method.1,13 This method is 
described in detail in the introduction chapter of the thesis. An example of a recording is 
shown in Figure 1A. 
 
Muscle Biopsy  
After the MFCV measurements, three muscle specimens (cylindric in shape with a length 
of 1 cm and a radius of 0.5 cm maximally) were taken by a Bergstrom needle (length 15 
cm) biopsy from the superficial part of the biceps brachii or quadriceps muscle (depth 
from skin to puncture place 3 cm). If the same muscle was used for MFCV recording and 
biopsy, care was taken to insert the biopsy needle at a site between the stimulation site 
and recording site of the MFCV study. Specimens mostly contained around 200 muscle 
fibers. One specimen per patient was taken for muscle fiber histochemistry and 
enzymehistochemistry. These specimens were quickly frozen in isopentane cooled by 
liquid nitrogen. Ten micron thick transverse sections were cut at minus 20° Celsius in a 
cryostat and were stained for fiber typing (myofibrillar ATPase after preincubation at pH 
4.2), so that type I fibers (darkly stained) and type II fibers (lightly stained) could be 
discerned. Both the smallest and largest type I and type II fibers were drawn using a 
drawing-microscope. Each drawn fiber area was transformed into a circle by hand using 
a template with several circular diameters. The matching diameter served as the 
measure for fiber size.12 Thus, four muscle fibers per patient were measured, providing 
the smallest and largest diameter for type I and type II fibers. 
 
Analysis  
For each patient, the slowest and fastest MFCV of the population of fibers measured and 
the smallest and largest MFD were used for the present analysis. Correlation between 
MFD and MFCV values and the significance of the correlations were calculated by linear 
regression analysis. 
    The validity of a linear relation was confirmed by counting runs, testing a significant 
deviation of the regression line from linearity (using GraphPad Instat version 3.05). 
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FIGURE 1. (A) MFCV study of a inflammatory myopathy patient : 5 traces superimposed, 
showing an identical response of several individual muscle fiber potentials to 5 subsequent 
stimuli. The fastest conduction velocity is 4.1 m/s (L1) and slowest is 1.7 m/s (L2), illustrating 
a wide range of velocities (distance of propagation: 5 cm). (B) Detail of the quadriceps 
muscle biopsy from the same patient, showing a severe increase of muscle fiber diameter 
variability (from atrophic to normal). Bar: 50 μm (hematoxylin-phloxine stained frozen 
section). 
        
 
    Such linear regression analysis was performed for the whole dataset and for each 
subgroup separately, for data sets obtained from the same muscle, and for data sets 
taken from a different muscle. As a next step, the analysis was performed using the 
diameters of type I fibers of type II fibers separately. The significance of any difference 
between the subgroups, between the measurements of the same muscle and different 
muscles was determined by multiple regression analysis. A linear contrast of a 
regression model with the diameters of fiber type I and type II was constructed to 
determine fiber type influence on the measurements. A p-value < 0.05 was considered 
significant. 
 
RESULTS 
 
Ninety-six patients older than 18 years were included. Of these subjects, 35 had a 
myopathy (4 patients had limb girdle syndrome, 5 dystrophic myopathy, 2 steroid 
myopathy, 3 nemaline rod myopathy, 5 mitochondrial myopathy, 3 acid maltase 
deficiency, 1 phosphorylase deficiency, 1 calcium-ATPase deficiency, 11 non-specific 
myopathy), 21 had an inflammatory myopathy (13 patients had polymyositis, 5  
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dermatomyositis, 3 inclusion body myositis), 1 had a neuromuscular junction disorder, 
and 15 had a neurogenic disorder (10 patients had motor neuron disease, 1 chronic 
inflammatory demyelinating polyneuropathy, 1 spastic paraparesis, 3 unclassified 
neuropathy). On the basis of the routine diagnostic work up, a quarter of the subjects (24) 
turned out not to have a neuromuscular disorder. The male-to-female ratio was 1:2 in the 
myopathies group and 1:1 in the other groups. Mean age was 49 ± 16 years in the 
myopathies group, 56 ± 4 years in the inflammatory myopathies group, and 56 ± 16 years 
in the neurogenic group. 
    MFCV studies and biopsies were performed in the same muscle in 53 subjects (24 in 
the brachial biceps and 29 in the quadriceps muscle). In 43 subjects MFCV was 
measured in the brachial biceps and the biopsy was taken in a different muscle (39 in the 
quadriceps muscle, 1 in the deltoid, 1 in the gastrocnemius, and 2 in the anterior tibial 
muscle). An example of the MFCV measurements and a biopsy sample of the same 
subject is given in Figure 1. 
    The correlations between the smallest MFD and the slowest MFCV, and between the 
largest MFD and fastest MFCV, are given in Table 1. The correlations in the disease 
groups were all significant, except for that for the largest MFD and the fastest MFCV in 
the neurogenic group. The correlation between the smallest MFD and the slowest MFCV 
was significantly higher (p = 0.05) in the neurogenic subgroup than in the myopathies 
 
 
TABLE 1. Correlation coefficients for the association between the smallest muscle fiber 
diameter (MFD) and the slowest muscle fiber conduction velocity (MFCV) (Rlow) and between 
the largest MFD and the fastest MFCV (Rhigh),including p-values for significance. 
 No. of studies 
Correlation 
coefficient Rlow
Correlation 
coefficient Rhigh
All subjects 96 0.58† 0.46† 
Measurements made in the same 
muscle  53 0.58† 0.58† 
Measurements made in different 
muscles  43 0.60† 0.26 
Myopathies 36 0.40* 0.46* 
Neurogenic disorders 15 0.82† 0.27 
Inflammatory myopathies 21 0.72† 0.47† 
* p < 0.05 
† p < 0.0005 
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FIGURE 2. Scatterplots and regression lines of the smallest muscle fiber diameter plotted 
against the slowest conduction velocity for (A) all subjects (r = 0.58), and for the groups of (B) 
patients with myopathies (r = 0.40), (C) patients with inflammatory myopathies (r = 0.72), and 
(D) patients with neurogenic disorders (r = 0.82), showing the correlation between diameter 
and conduction velocity. 
 
 
subgroup. The scatterplots for the smallest MFD and the slowest MFCV are presented in 
Figure 2 for all subjects, including the cases without a neuromuscular disease (A), and 
separately for the myopathies group (B), the inflammatory myopathies group (C), and the 
neurogenic group (D). Equivalent scatterplots for the largest MFD and the fastest MFCV 
are presented in Figure 3. 
    The data of the largest MFD and the fastest MFCV in the myopathies group (Figure 3, 
B) contained one outlier. The correlation between the largest MFD and the fastest MFCV 
was significant in the whole group (p= 0.001) but not in the myopathies group, when this 
outlier was removed from the analysis. None of the regressions deviated significantly 
from linearity. 
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FIGURE 3. Scatterplots and regression lines of the largest muscle fiber diameter plotted 
against the fastest conduction velocity for (A) all subjects (r = 0.46), and for the groups of (B) 
patients with myopathies (r = 0.46), (C) patients with inflammatory myopathies (r = 0.47), and 
(D) patients with neurogenic disorders (r = 0.27), showing the correlation between diameter 
and conduction velocity. 
 
 
    The correlation between smallest MFD and slowest MFCV of measurements made in 
the same muscle did not differ from measurements made in different muscles (Figure 4, 
A, and B). The correlation between largest MFD and fastest MFCV was significant if the 
measurements were made in the same muscle but not if they were made in different 
muscles (Figure 4, C, and D). 
    In the whole group, mean smallest MFD of type II fibers was significantly lower then 
that of type I fibers (p <  0.001). Mean largest MFD of type I fibers was significantly higher 
than that of type II fibers (p < 0.005). The regression model showed that the slowest 
MFCV was mainly dependent on smallest type II fibers, while the fastest MFCV was 
mainly dependent on largest type I fibers. 
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FIGURE 4. Scatter plots and regression lines of the smallest muscle fiber diameter plotted 
against the slowest conduction velocity for samples taken in (A) the same muscle (r = 0. 58) 
and (B) in different muscles (r = 0.60), and of the largest muscle fiber diameter plotted against 
the fastest conduction velocity for samples taken in (C) the same muscle (r = 0.58) and (D) in 
different muscles (r = 0.26). 
 
 
    Figure 5 shows the combined data for the smallest MFD and slowest MFCV and for the 
largest MFD and fastest MFCV. For the whole dataset, the best fitting linear equation 
was MFCV (m/s) = 0.043*MFD (μm) + 0.83. In the subgroups, this equation was MFCV = 
0.043*MFD + 0.90 in the myopathies group, MFCV = 0.042*MFD + 0.70 in the 
inflammatory myopathies group, and MFCV = 0.049*MFD + 0.53 in the neurogenic 
group.  
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FIGURE 5. Scatterplot of the 
associations between the smallest 
fiber diameter and the slowest 
conduction velocity (□) and between 
the largest fiber diameter and the 
fastest conduction velocity (■) for all 
patients. The solid regression line is 
represented by the equation of MFCV 
= 0.043*MFD + 0.83 and was derived 
from our data. The dotted line 
represents the relation suggested for 
normal muscle fibers 
(MFCV=0.05*MFD + 0.95).8
 
 
DISCUSSION 
 
Our results show the validity of assuming a linear, albeit not a proportional, relation 
between propagation velocity and fiber diameter in vivo in neuromuscular patients. The 
relation found for the whole population closely resembles the relation estimated for 
normal healthy muscle.7 We found only small differences between the different types of 
underlying neuromuscular disorder. The correlations remained significant if 
measurements made in two different muscles were included, suggesting a generalized 
disorder. The significant correlations suggest that a minimum of 25 muscle fiber 
potentials as a sample size is sufficient. 
 
Relation between velocity and diameter 
 
The “overall” relation between MFCV and MFD (MFCV = 0.043*MFD + 0.83) in patients 
with a neuromuscular disease is remarkably similar to that estimated for normal 
individuals (MFCV = 0.05*MFD + 0.95).8 This is the case, despite the fact that the latter 
equation was based on MFCVs recorded from healthy subjects in combination with 
independently obtained fiber diameters taken from the literature, whereas our results are 
based on an intrasubject observation of MFCV and MFD. Despite the differences 
between the subgroups, discussed later, overall a relative independence on pathological 
factors has been found. This confirms the observations in membrane simulation studies 
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that, both in nerve and muscle fibers,  conduction velocity depends mostly on fiber 
diameter, more than on all the other factors implemented, even in myelinated nerve 
fibers.7,15 As suggested in the introduction, the relative independence of secondary 
factors, next to diameter, indeed opens the use of MFCV as a predictor of fiber size, not 
only in patients, but also in other applications where a non-invasive determination of 
muscle fiber diameter can be important, e.g. in the elderly or in space physiology.11
 
Myopathies versus neurogenic disease 
 
The correlation between the smallest MFD and the slowest MFCV was significant in the 
myopathies group, although significantly lower than that in the neurogenic group. The 
regression line was less steep and the y-intercept was higher (Figure 2, B, and C). The 
regression equation for the neurogenic group came closer to that for normal muscles 
than the equation for the myopathic group did. This indicates that for the smallest fibers, 
factors other than fiber diameter have more influence on MFCV in myopathies than they 
have in neurogenic disease or health. 
    One of these factors may be a lesion of the sarcolemma, which has previously been 
suggested to disturb propagation.2,4 Fiber splitting may be another contributing factor. It 
is conceivable that in some myopathies, especially those characterised by severe 
intracellular damage or extensive sarcolemmal degradation, the propagation of action 
potentials fails in an early stage before fiber atrophy. 
    In contrast to the correlation of the smallest MFD and the slowest MFCV, the 
correlation between the largest MFD and the fastest MFCV was significant in both 
myopathies group but not in the neurogenic group. It seems that the smaller range of 
maximal velocities  and of thickest fibers in the neurogenic group than in the other groups 
explains this finding. Or, from a different perspective, the higher correlation between the 
largest MFD and fastest MFCV in both myopathies group can be explained by the 
presence of outliers (Figure 3, B, and C), which were only found in the myopathies group. 
Although they may be outliers statistically, they are not measurement artifacts. It is 
remarkable that, in a specific patient the maximal diameter was unmistakably 292 μm 
and the highest MFCV indeed 12 m/s. High MFCVs, up to 15.8 m/s, were also measured 
in two other subjects, also in combination with (not proportionally) hypertrophic fibers. So, 
high MFCVs do actually occur in the myopathic  conditions, as a result of extreme fiber 
hypertrophy. It should be noted that stimulation of a nerve twig rather than the muscle 
fiber may lead to falsely high MFCVs. This is further discussed in the limitations of the 
study section. 
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Type I fibers versus type II fibers 
 
The type II fibers showed significantly more atrophy than the type I fibers, as has been 
observed previously.2,6 Fiber hypertrophy was significantly more pronounced in type I 
fibers, which was expected, because these fibers are usually larger. This dependency of 
fiber type and atrophy or hypertrophy resulted in a fiber type dependency of MFCV in the 
multivariance analysis. This implies that we have measured the MFCV of either the 
slowest or fastest fiber, and independent of fiber type. 
 
Influence of the site of measurements 
 
Interestingly, the correlation between the smallest MFD and the slowest MFCV remained 
significant, even if the two measurements were made in different muscles. The spectrum 
of muscle fiber sizes in controls is quite different between the biceps (30-70 μm) and 
quadriceps (50-95 μm) muscles.9 Fiber atrophy, however, brings down the diameters to a 
small range in both muscles, thus nullifying the initial difference. The correlation 
coefficients between the largest MFD and the fastest MFCV were influenced by several 
outliers in the myopathies group, as indicated before. If these outliers were removed, 
both correlations were not significant. In contrast to atrophy, fiber hypertrophy may 
further amplify the difference between biceps and quadriceps muscle fiber diameters in 
the upper range. 
 
Limitations of the study 
 
Although we established the apparent relationship between the diameter and conduction 
velocity of single muscle fibers in vivo, this relationship cannot be verified on individual 
muscle fibers because it is technically virtually impossible to measure propagation 
velocity and diameter from one and the same fiber in vivo. Both MFD and MFCV 
measurements were affected by sampling errors because only a small proportion of all 
fibers were measured; unfortunately, it is not possible to determine the magnitude of this 
sampling error. 
    Another, more minor, drawback of the technique for measuring MFCV is uncertainty 
about the distance between the stimulation and recording electrodes, which may 
especially be a problem if fibers run skew with respect to the needle insertion sites. As 
mentioned before, another pitfall of the method is the possibility to stimulate nerve-twigs 
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instead of muscle fibers directly. This gives rise to a potential with a different morphology 
and preceding the direct fiber responses. It will also invariably cause a gross muscle 
twitch, which can be used to make the distinction with direct muscle fiber responses.13
 
    In conclusion, we have demonstrated that the relation between MFCV and MFD 
appears to be linear, and that it closely resembles a relation found in normal muscle. 
Only small differences between myopathic and neurogenic disorders are found with 
respect to this relation.  
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ABSTRACT 
 
Muscle fibre conduction velocity (MFCV) was measured following trains of 10 stimuli at 
interstimulus intervals of 1 to 50 Hz. A significant MFCV increase of 17% of the fastest 
fibres compared to a single stimulus response was found, following trains of 20 and 50 
Hz stimulation. In contrast, no significant increase of MFCV was found for the slowest 
fibres. Our data suggests that supernormal MFCV due to the velocity recovery function is 
fibre type dependent. We propose that the mechanism of the velocity recovery function is 
related to the intracellular calcium level. 
 
 
3. High frequency stimulation 57
INTRODUCTION 
 
The conduction velocity of action potentials along the sarcolemma is dependent on the 
interval between discharges. The velocity recovery function (VRF) determines that 
following a discharge, muscle fibre conduction velocity (MFCV) may increase to up to 
115% of normal, reaching a peak after 8-12 ms.7 Hereafter, a nearby exponential decay 
follows, with normal MFCV being reached after 500-1000 ms.4,7
    Although the characteristics of type I and type II muscle fibres are different in many 
respects, a different VRF for type I fibres and type II fibres has not been reported. We 
hypothesized that the effect of the VRF in type II fibres would be significantly larger than 
in type I fibres. We measured, invasively, the increase of MFCV in response to short 
trains of stimuli at various frequencies. 
 
METHODS 
 
Thirteen healthy subjects (5 male, 8 female, 19-22 years) were tested. None of the 
subjects had prior complaints of the neuromuscular system. MFCV was measured using 
an invasive EMG technique which is described in detail in the introduction of this thesis.1  
    First, a test measurement was made using a single stimulus (stimulus strength: 2-10 
mA, stimulus duration: 0.05 ms). Hereafter, the stimulus protocol was set to a train of 10 
stimuli, while stimulus strength and duration were not changed. The stimulus rate was 
sequentially increased from 1 to 3, 5, 10, 20, and 50 Hz, with a 10 seconds interval of 
rest before each increment. The spikes evoked by the last stimulus of a train of 10 were 
used for analysis. The last measurement in the train of stimuli at 1 Hz was used as 
baseline MFCV (MFCV1). 
    Fastest MFCV (MFCVf) and slowest MFCV (MFCVs) were calculated, using the 
latencies, measured at the positive peak, of the first and the last spike of the complex. 
The estimated distance of propagation was the distance between stimulating and 
recording electrodes measured at the skin. 
    Difference between results of all stimulation frequencies were compared using a 
Student-Newman-Keuls Multiple Comparisons Test. We also tested whether a linear or 
non-linear trend was present when an increment of MFCV was found.  
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TABLE 1.  Mean slowest (MFCVs) and fastest (MFCVf) MFCV of the last recording of a train 
of 10 stimuli at various rates of interstimulus intervals, and relative increase to the baseline 
MFCV at 1 Hz (MFCV1). 
 Stimulus rate 
 1 Hz 3 Hz 10 Hz 20 Hz 50 Hz
Mean MFCVs (m/s) 3.2 3.3 3.5 3.4 3.6 
Mean % increase vs MFCV1  1% 6% 3% 9% 
      
Mean MFCVf (m/s) 4.0 4.3 4.6 4.7* 4.9* 
Mean % increase vs MFCV1  3% 10% 17% 17% 
           * p< 0.01 compared to MFCV1
 
 
RESULTS 
 
MFCVf and MFCVs gradually increased with increasing rate of stimulation (Table 1). The 
increment was significant for MFCVf at 20 Hz and 50 Hz. A significant linear trend was 
found for the increment of MFCVf (slope, 0.2133; r squared, 0.1817; p value, 0.0018), but 
not for MFCVs. 
 
DISCUSSION 
 
We were able to measure supernormal MFCV in the fastest conducting muscle fibres, but 
not in the slowest conducting fibres. The difference in baseline conduction velocities 
between fibres can be explained by the difference in mean fibre diameter,1 which is larger 
in type II fibres.6 Our data therefore suggests that the VRF effect is present in type II 
fibres, but not in type I fibres. 
    The mechanism behind the VRF is largely unknown.  An enhanced sodium-potassium-
ATPase activity, triggered by exercise in order to restore and maintain sarcolemmal ionic 
concentrations, is an obvious candidate mechanism. However, this effect takes only 
place after several seconds.2,5 Although enhanced sodium-potassium-ATP-ase activity 
may contribute to enhanced propagation velocity, it can therefore not explain our results. 
The time course of the VRF suggests a mechanism directly related to changing ionic 
concentrations, rather than a secondary mechanism. 
    Our data suggest that the VRF is related to a fibre-type dependent mechanism. The 
differences in the speeds of contraction between type I (slow-twitch) and type II (fast-
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twitch) fibres can be explained, in part, by the rates of release of calcium by the 
sarcoplasmatic reticulum and by the activity of myosin-adenin-triphosphatase. Both of 
these characteristics are faster and greater in the FT fibres.3 Furthermore, it is known that 
an increase of the intracellular calcium levels facilitates propagation through modulation 
of the sarcolemmal voltage-gated sodium channels. The depolarisation threshold for 
sodium channels is lower if the intracellular calcium concentration is higher, thus 
increasing propagation velocity. 
 
    We therefore suggest that supernormal MFCV is related to an increased level of 
intracellular calcium. If the interval between discharges is short, the calcium-adenin-
triphosphatase pumps cannot restore the normal level of intracellular calcium. A slightly 
elevated level remains, resulting in  increased propagation velocity that is more 
pronounced in type II fibres. 
    Other modulating effects of calcium on sodium channels have been described in more 
detail in human cardiac muscle tissue. In these fibres, intracellular calcium has a slow 
inactivation gating effect on the sodium channels. This effect is generated through direct 
binding of calcium ions to the sodium channel, and through binding of calmodulin, a 
calcium sensing protein, to sodium channels in a calcium-dependent manner.8,9 
However, slow inactivation in skeletal muscle tissue is beyond the time course of the 
VRF.  
    Estimates of motor unit size by standard EMG techniques are biased by type I units, 
because these are recruited first due to the size principle. MFCV measurements, being 
independent of voluntary contraction, are not biased by fibre type.1 Our current results 
suggest that, by adding measurements of the VRF effect to standard MFCV 
measurements, a new method could be introduced that might help in the discrimination of 
fibre type specific myopathies. These include disuse atrophy, and steroid induced 
myopathy.  
 
Acknowledgments: We would like to thank H.J. Schelhaas for his critical review of the 
manuscript. 
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ABSTRACT 
 
We observed a sudden shortening of the latency to an individual single fibre spike 
component followed by a gradual return to baseline values during stimulated single fibre 
electromyography (SFEMG) of the facial muscle. The pattern could be reproduced in 
healthy controls. The sudden decrease in latency proved to follow an additional 
discharge of the muscle fibre, not due to the external stimulus. This additional discharge 
was identified as an F wave. The mechanism is thought to be a higher muscle fibre 
conduction velocity resulting from a temporary increase in stimulus frequency, in the form 
of an extra impulse along the muscle fibre represented by the F wave. The typical 
abnormal pattern should be recognised because it can falsely increase the mean jitter. 
We advice to increase the timebase to 50 milliseconds if this pattern is observed and to 
exclude the affected potentials from jitter measurements. 
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INTRODUCTION 
 
Axonal-stimulated single-fibre electromyography (SFEMG) is a sensitive technique to 
examine the neuromuscular junction. Major pitfalls of SFEMG include direct muscle fibre 
stimulation, near-threshold stimulation of the axon, and intermittent stimulation due to 
spurious blocking or extra discharges.5,7 We have observed a sudden decrease of the 
latency of individual fibre potentials that appeared to be artificial, but could not be 
attributed to these known pitfalls. We have tried to reproduce the sudden shortening of 
latency in a healthy control to find an explanation.  
 
CASE REPORT 
 
The sudden shortening of latency was observed several times in the University Hospitals 
of Leiden, Uppsala and Nijmegen. Representative examples of the shortening of latency 
of two patients with non-specific complaints of generalized fatigue are shown (Figure 1). 
No signs of a neuromuscular disorder were found in both cases after extensive nerve 
conduction studies, and needle electromyography in several muscles. Repetitive nerve 
stimulation of the ulnar nerve had been shown to be normal before and after facilitation. 
Stimulated SFEMG of the frontalis muscle was performed using a standard protocol.4 
The temporal branch of the facial nerve was stimulated at 10 Hz (stimulus strength: 2-8 
mA, duration 0,2 ms) with a monopolar needle and a surface electrode. A single fibre 
electrode was used to record single fibre responses to 50 stimuli of the frontalis muscle. 
At least 20 fibres were measured. An automated algorithm that rejects extreme values 
was not available in the equipment used for the recordings. 
    Abnormal jitter of up to 84 microseconds was measured in several recordings, shown 
in Figure 1. All other measurements of the frontalis muscle showed normal jitter and 
blockings were not found. The abnormal recordings  displayed a  sudden drop in latency 
of 250-300 microseconds, followed by a gradual return of the latency to the baseline 
values. This pattern repeated itself a few times within one measurement. 
 
HEALTHY CONTROL 
 
In order to reproduce the effect, stimulated SFEMG of the frontalis muscle was 
performed on a healthy subject using the same protocol. After several measurements, an 
identical pattern of repeating sudden shortenings of latency of around 300 microseconds 
with a gradual return to the baseline value was observed (Figure 2). Abnormal jitter of 47  
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FIGURE 1. Stimulated SFEMG from two patients. (A) 50 sweeps superimposed, with (B) the 
corresponding “interpotential interval diagram (IPI)”, i.e. latency between stimulus and spikes, 
of one patient, showing the typical pattern of sudden shortening of latency and gradual return 
to baseline. The measured jitter of the potential was 84 microseconds. (C, D) Example of the 
same pattern, recorded in another patient in two measurements. Jitter was 35 microseconds 
in C and 59 microseconds in D.  
 
 
microseconds was measured. The time base of the recording was then extended to 50 
ms sweep duration, revealing another potential, similar in shape to the recorded fibre 
potential but with a longer latency (28 ms), and only occurring in a minority of the 50 
recordings. Interestingly, the latency shift usually affected only one of many spikes in a 
complex recording, as shown in the diagram in Figure 2(C). The late component had the 
same shape as the spike showing the latency shift. A similar pattern was encountered in 
several other subjects and could be related to the appearance of a late potential after 
increasing the time base of the recordings. 
 
DISCUSSION 
 
These observations showed that the sudden shortening of latency of the potentials 
evoked by axonal stimulation was caused by the additional potential that immediately 
preceded it. This potential was similar in shape to the muscle fibre potential evoked by 
the external stimulus, and occurred at a relatively invariant interval after the preceding 
evoked discharge. The resulting increased jitter might be mistaken for a disturbance of 
the neuromuscular junction. Several arguments suggest that the late potential is in fact a 
facial F wave, and that the latency shift is not due to disturbed neuromuscular 
transmission. 
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FIGURE 2. Stimulated SFEMG of the healthy control. (A) 50 sweeps superimposed, time 
base adjusted to 5 ms per division. Two separate complexes of potentials are recored (1, 2), 
as well as the F-response at 28 ms (3), resembling complex 2 in shape. (B) 5 single traces 
including the F-response (trace 27) and the sudden shortening of latency after the F-
response (trace 28). (C) Interpotential intervals (IPI), i.e. latency between stimulus and 
spikes, in microseconds of the first complex of potentials (1) and the second (2). The intervals 
corresponding with traces 27 and 28 are indicated with the lines. Note that subsequent to the 
F-response, the second potential shows a sudden latency drop, but the first complex does 
not. Jitter of the spike of the first complex was 23 microseconds and of the spike of the 
second complex 47 microseconds. 
      
  
    First, the latency of the late potential is similar to reported superficially measured F-
response values of 15-23 ms for the frontalis muscle.2 The latency of the F-response of 
the individual fibre can be expected to be longer than that of the F-wave, as the site of 
excitation in SFEMG is closer to the muscle, and the recorded fibres may reflect some 
later portion of the F-wave rather than its very first deflection. Second, the similarity of the 
shape of the late potential and the recorded muscle fibre potential suggests that they 
originate from the same muscle fibre and thereby from the same axon, suggesting 
backfiring of the corresponding motor neuron. This is confirmed by the fact that the  
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latencies of the potentials with a different shape, apparently belonging to different motor 
neurons, were not affected by the F-response. Third, the low frequency of  occurrence of 
the late potentials is  comparable with the reported F-wave frequency of 2%-30%.8 In the 
orbicularis oculi muscle, some motor neurons may rarely backfire, while others seem to 
do it abundantly.9 It has been our experience that F-response interference is not a rare 
phenomenon in stimulation SFEMG. Even so, during the 50-100 stipulations typical of a 
complete study from one site, it may occur by chance only once in about every one or 
two studies. 
 
    We presume that the mechanism of the sudden decrease of the latency is related to 
the muscle fibre velocity recovery function (VRF) (Figure 3). After a fibre discharge, 
propagation velocity along the muscle fibre is reduced by up to 22% for about 6 ms. This 
is followed by a period of super normality, reaching a peak at about 8-12 ms, when 
velocity may amount to as much as 115% of normal.3 Hereafter, an exponential decay 
follows, with half of the supernormal conductivity disappearing within 100 ms, and normal 
conduction velocity being reached after 500-1000 ms.1,3 The increase in velocity may be 
even more pronounced during repetitive activity, which suggests a cumulative effect. 
    During 10 Hz  stimulation in SFEMG, the interstimulus interval is constant at 100 ms, 
resulting in a constant muscle fibre conduction velocity. Introducing an F-response 
effectively shortens the interval to the stimulus, following the F wave to about 75 ms. The 
muscle fibre conduction velocity of the response to the external stimulus following the F-
response will then be higher (Fig. 3), and the potential will therefore be picked up earlier 
by the SFEMG needle. The magnitude of the VRF effect will depend on the distance of 
propagation between the endplate and the single fibre needle, and on the strength of the 
VRF. The effect of the increased stimulus frequency will diminish over a longer period of 
time, resulting in a gradual return to the baseline contribution of the VRF. If the recording 
electrode is very close to the endplate, the VRF effect will probably not be recorded at all. 
Possible effects of latency shifts in nerve conduction or neuromuscular transmission time 
can be excluded with the present time interval changes. In this light, it should be noted 
that the endplates of the frontalis muscle appear to be more widely scattered than those 
of the orbicularis oculi muscle, thus increasing the possibility of F-response interference 
in the frontalis muscle. 
    Jitter due to variation of muscle fibre conduction velocity has been called ‘myogenic’ 
jitter.6,7 It has been observed in the presence of blockings, irregular voluntary activation 
and near-threshold stimulation. In these circumstances the activation rate of the fibre is 
decreased, resulting in a longer latency. The size of the effect of the VRF is usually  
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FIGURE 3. Muscle fibre conduction velocity recovery function. (I) Refractory period. (II) 
Subnormal conductivity. (III)  Supernormal conductivity. (IV) Gradual return to baseline. CV, 
muscle fibre conduction velocity. Derived from Mihelin et al.1
 
 
smaller, ranging from tens of microseconds up to 200 microseconds,7 as compared to the 
250-300 microseconds increment after an F-response. The strength of the VRF itself 
varies from fibre to fibre, and the size of the effect is linearly correlated with 
the response latency. A typical pattern of latency changes related to blockings or 
irregular voluntary activation has not been reported. 
    The time base of SFEMG recordings is usually set at 20 ms, with 2-4 ms for the pre-
stimulus period. Thus the F-response will not be visible in normal settings, although it can 
be detected on audio. We recommend that the electromyographer learns to recognise 
the sudden shortening of latency as something not due to synaptic dysfunction. The 
presence of the F-response can be demonstrated by increasing the time base to 50 ms. 
Patients with a neurological disorder in which F waves are easily evoked may be 
particularly prone for F-response interference in SFEMG. Care should be taken in the 
interpretation of stimulated jitter if a disorder leading to increased facilitation of F waves is 
present, such as Parkinsons disease, and cortical or pyramidal lesions. It should be 
added that these findings are made in all muscles with a frequency that is dependent on 
their likelihood to give F-responses upon nerve stimulation. It is therefore a general 
phenomenon to be noticed during stimulated SFEMG. 
    This report also demonstrates the importance of visual inspection of the latency 
diagram.  The SFEMG studies in both patients showed abnormal jitter, but after rejecting 
the artificial abnormal latency shortenings the SFEMG studies of both patients were 
concluded to be normal. The use of a computation algorithm would exclude those latency 
shifts that exceed the set value (for example individual IDI value > 4 MCD, obtained for 
the 100 stimulations). Such an algorithm is, however, not available in all equipment, and 
furthermore, those latency shifts that do not cross the rejection level may still be included. 
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Visual inspection of the time histogram, and manual editing of data is recommended. It 
should also be noted that expressing the jitter as MCD attenuates the effect on the 
calculated jitter value of the short trends when latencies gradually return to the baseline. 
We usually find the effect of the F-response interference to be small and without 
significant importance for a final conclusion of a study, unless the presence of F-
responses is pathologically increased. 
    In conclusion, we have demonstrated that interference of F-responses in stimulated 
SFEMG leads to a typical pattern of abnormal latency measurements. This important 
pitfall should be recognised for what it is, and the affected potentials should be excluded 
from jitter measurements. 
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5 
 
 
Introduction to qualitative and quantitative EMG 
techniques 
 
 
Neurography and nEMG are the principle clinical neurophysiologic tools in the diagnosis 
of a neuromuscular disease. The former means to measure the number of axons in motor 
and sensory nerves, and the conduction velocity of impulses along them. The latter 
means to measure action potentials from motor units during voluntary contraction, using 
a needle electrode that is inserted into the muscle. 
    For a new technique, such as MFCV studies, to be established as a diagnostic tool, a 
comparison with the gold standard must be made. I will therefore provide the reader with 
some background of the golden standard, by discussing nEMG and MUPs in more detail. 
An overview of available EMG techniques is included.7
 
THE MOTOR UNIT POTENTIAL IN MORE DETAIL 
 
As explained in the introduction, a MUP is the summation of action potentials of the 
active fibres of the motor unit. The arrival of an individual fibre potential at the tip of the 
electrode is determined by two factors: spatial distribution of the fibers, being the 
distance between the electrode and the active fibre, and temporal distribution, being the 
time needed to travel the distance between the endplate and the needle. The latter 
depends on the propagation velocity of the action potential along the sarcolemma. 
    The variability of spatial and temporal distribution within a motor unit determines the 
morphology of a MUP. If the needle electrode is far away from the active fibres, the 
shape of the MUP will be more blunt and less complex. If the needle electrode is close to 
the fibres, but far away from the endplate zone, then the mutual differences in 
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propagation velocity of fibres will become more pronounced, leading to a more complex 
shape of the MUP. The optimal site for an electrode would be close to the active fibres, 
and not too far away from the endplate zone. However, the examiner can never be 
precisely sure about the location of his needle. The shape of the MUP continuously 
changes, while moving the needle through the muscle, and this can be used to estimate 
the distance of the needle to the active motor unit fibers. Further contributing to MUP 
variability are the density of fibres within the activated motor unit, and the size or radius 
of its territory (spatial factor). Furthermore, changes in propagation velocity, for example 
related to a change of firing frequency, will affect the MUP (temporal factor). The 
variability of the MUP due to spatial and temporal factors is an important source of error 
in needle EMG. 
 
    A MUP consists of two components: the first and ‘main’ segment, and a second 
‘terminal’ segment which is a long positive terminal waveform of low amplitude (Figure 1). 
The main segment is the waveform that is usually evaluated by the electromyographer, 
and which will be discussed in more detail. The terminal segment mirrors the true 
morphology of the intracellular action potential, which is monophasic positive.4 Its mean 
duration is 24 (± 4) milliseconds. It is basically ignored in routine clinical concentric 
needle EMG, often not even visible. 
 
 
FIGURE 1. A single motor unit 
potential (MUP) as recorded 
with a concentric needle 
electrode.  
 
 
    The following attributes of the main segment of a MUP are recognised: duration, 
amplitude, the number of phases, and  its firing frequency. 
    The duration of a motor unit potential is counted from the first to the last positive 
deflection of the main segment. The terminal segment is not taken into account. Normal 
MUP duration ranges from 5-15 ms, but 8-12 ms is a more commonly used range.2 Both 
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spatial and temporal distribution determine the duration of a MUP, and duration is 
considered to be the most important attribute. MUPs of shorter duration can be found in 
myopathies (small motor unit territory), MUPs of longer duration in neurogenic disease 
(large motor unit territory).1
    The amplitude is measured from the highest to the lowest value of the whole potential. 
Normal MUP amplitude varies between 1000 and 4000 μV.2 The amplitude represents 
the summation and cancellation of the amplitudes of the active muscle fibres. Lower 
amplitudes are found in myopathies (motor units with few fibres), and higher amplitudes 
in neurogenic disorders (units with many fibres).1
    The number of phases is increased by one each time the potential crosses the 
baseline. This count should not exceed 4 in normal muscle. Polyphasia means more than 
4 phases, and is mainly a reflection of the temporal distribution of the active fibers. It is a 
non-specific finding, which can occur in any neuromuscular disorder, but also if the 
recordings are made far away from the endplate. 
    The attributes of a MUP vary between different types and sizes of motor units. For 
example, MUPs belonging to a type I motor unit are of shorter duration and lower 
amplitude values than MUPs belonging to a type II motor unit. Also, MUPs recorded in 
the deltoid muscle are shorter and smaller than those recorded in the rectus femoris 
muscle. 
 
QUALITATIVE ELECTROMYOGRAPHY 
 
Needle EMG is primarily performed qualitatively. By this we mean that the 
electromyographer looks at and listens to the electrical activity that he is recording in 
real-time. After insertion of the needle, the muscle is first examined at rest, in order to 
record any spontaneous muscle fibre discharges. These can arise from muscle fibres 
with unstable membrane potentials, due to denervation, ion channel dysfunction, or other 
causes. Although the detection of spontaneous muscle fibre discharges is an important 
aspect of nEMG examination, I will not elaborate any further on this subject. 
    Next, MUPs are recorded and evaluated, while the subject voluntarily contracts the 
muscle. In order to reliably assess the attributes of a single MUP, it must be recorded as 
a distinct waveform. This implies recording at low force. 
    There are two mechanisms that regulate force control: recruitment, and firing rate. At 
the start of a contraction, the first unit in order will be activated at a firing rate of 
approximately 8 Hz. Increasing the force will increase the firing rate of this unit. A second 
motor unit will be activated as soon as the first one fires at a certain rate, usually around 
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10 Hz. This sequence is repeated until all units are firing at their maximum rate, which 
can be up to 40 Hz. As said in the introduction, the size principle dictates that small type I 
units are recruited first, and large type II units only at higher force levels.8
    Interference scrambles the shape of single motor units, if many motor units are firing at 
high rates. This is why duration and amplitude of individual MUPs can only be assessed 
at low force levels. Motor units that are activated above 30% of maximum voluntary 
contraction cannot be assessed individually. Tthe size principle then dictates that one 
can evaluate small type I motor units, but not large ones. 
    At higher force levels, information must be obtained from the summation of electrical 
activity of  many motor units firing simultaneously. This is called the interference pattern. 
One way to interpret the complexity of the interference pattern would be to relate the 
electrical power to the level of generated force. It is however not practical, and very time-
consuming, to implement quantified force measurements in routine nEMG examination. 
    Nevertheless, the examiner usually applies counterforce to the voluntary contraction of 
the patient, while performing an nEMG examination. This subjective force measurement 
can be used as a reference. It is especially useful in the evaluation of the recruitment 
pattern of the units. In myopathies, motor units have lost muscle fibres, and thus 
generate less force per unit. This is compensated for by recruiting more motor units at a 
given level of force. In neurogenic disorders, α-motor neurons or motor axons are 
affected, and their attached muscle fibers lose their innervation (‘denervation’). In 
response, nerve twigs from adjacent motor units will sprout and restore innervation (‘re-
innervation’). This unit now has more fibres, and can generate more force, but in total, 
fewer units are available. The recruitment pattern will be diminished, and firing rates of 
individual motor units increased. A so-called ‘single-unit’ pattern is the most extreme 
neurogenic situation, in which all force of a given muscle is generated by 1 huge motor 
unit. 
    It can be argued that measurement of force, in a strict sense, is unnecessary, if a 
contraction is made at best effort, so-called ‘maximum voluntary contraction’. 
Theoretically, most motor units available  should be recruited and firing at maximum rate 
during maximum contraction. This notion is used in nEMG examination: assessment of 
the interference pattern that is generated by all active motor units at maximum voluntary 
contraction is a standardised test condition. The screen should be filled with activity and 
the horizontal baseline should not be visible in an epoch of 200 ms. Normal boundaries 
of the envelope that can be drawn between the lowest and highest amplitude in this 
epoch are between 2000 and 5000 μV. In myopathies, the amplitude envelope will be 
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lower. In neurogenic disorders the amplitudes will be higher, and the baseline will 
become visible as a result of the loss of motor units. 
By assessing these attributes of MUPs at low force contraction, and of the interference 
pattern at high to maximum voluntary contraction, the electromyographer is able to 
reliable distinct normal from  abnormal, and myopathic from neurogenic abnormalities. 
 
    Several drawbacks of nEMG should be considered. 
    The technical bias. This refers to the influence of the placement of the needle in 
relation to the muscle fibres of the motor unit and their endplates, as has been explained.  
The variation in the shape of MUPs can be quite significant due to spatial and temporal 
factors. 
    The recruitment bias. As said before, only type I units can be assessed individually, 
due to the size principle of voluntary contraction. As such, nEMG assessment is always 
biased by small units. 
    The patient bias. Adequate cooperation of the patient is required. In some disorders, 
patients cannot contract their muscles, for example in quadriplegic critical illness 
myopathy, or coma. Other patients may be unable to maintain a contraction at low or high 
force level, a phenomenon that may be seen, for example, in psychosomatic disorders. 
Moreover, contracting a muscle with a rigid needle electrode inserted in it, can be rather 
painful. This may especially be a problem in children.   
    The investigators bias. As with any other examination, the eye of the beholder is a 
potential source of error. Many electromyographers perform a quick clinical examination 
of the patient, prior to the EMG. The interpretation of the EMG will then be influenced by 
the findings of the clinical examination, especially if the EMG is borderline abnormal. 
Furthermore, EMG is most often obtained from multiple muscles. It is very likely that the 
results from one muscle will be taken into account, consciously or not, when assessing 
another muscle. 
 
Clinical application of qualitative electromyography 
 
The quality of the visual and auditory  subjective assessment depends largely on the 
experience of the electromyographer, but has proven to be reliable in the past 50 years 
that it has been done. The examination can be done quickly, usually within a few 
minutes, and most muscles are relatively easy accessible to the needle electrode. 
Nevertheless, a rather large inter-observer variability has been described.6,9
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    Diagnostic sensitivity of qualitative nEMG for diagnosing myopathies is around 80%, 
with some variation between specific diseases.3 Specific patterns that could distinguish 
different causes of myopathies were not identified. Spontaneous discharges of muscle 
fibres were found in inflammatory myopathies, but also in dystrophic myopathies, and 
others. Specificity has been reported to be as low as 65%, to as high as 90%. The low 
specificity is in part related to the effect of the positioning of the needle on the 
morphology of the MUP, as discussed earlier.  
 
QUANTITATIVE ELECTROMYOGRAPHY 
 
There have been many attempts to improve the scoring of nEMG. Already in the early 
1950s, recorded signals were taped and manually measured post-recording. The digital 
era simplified matters enormously with the introduction of several automated techniques. 
More recently, complex statistical methods have been suggested, as well an artificial 
neural network technique. The role of these new methods in the diagnosis of myopathy 
has not yet been clarified. 
    Despite the technological progress, subjective qualitative assessment remains the 
standard of practice.  None of quantitative automated methods has proved to be superior 
to the subjective method in diagnosing neuromuscular disorders. Now follows a short  
overview of the various methods of quantitative EMG in electrodiagnosis. 
 
Quantitative MUP analysis 
 
The ‘older’ quantitative manual analysis of individual MUPs yielded a sensitivity of 72%-
89% when applied to selected patients with clear-cut affections, and healthy controls.3 
Mean duration was most contributing, polyphasia increased sensitivity further, but 
amplitude did not contribute to diagnostic yield. Applying automatic analysis of averaged 
motor unit action potentials did not increase the diagnostic yield.11 In a series of 
unselected patients, sensitivity was 46% for myopathies, and 38% for neuropathies. 
    Probably the greatest disadvantage of quantitative MUP analysis is its examiner 
dependence.13 The sampling of MUPs depends on the examiner’s skill, and especially 
the small ‘myopathic’ ones can be difficult to sample. A second factor prone to be 
subjectively influenced is the measurement of MUP duration. This can be ambiguous 
especially for long duration MUPs which reach the baseline asymptotically at their end. 
Finally and similar to qualitative MUP analysis, a recruitment bias, a technical bias, and a 
patient bias are present. It may be obvious that the potential sources of error due to the 
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position of the electrode in relation to the active fibres and their endplates will not be 
solved by quantitative automated EMG analysis.  
 
Quantitative interference pattern analysis 
 
Manual analysis of the number of phase reversals of the signal of the interference pattern 
was introduced by Willison in 1964.5 A ‘turn’ is defined as a phase reversal of the signal, 
if the amplitude between two turns is at least 100 μV. The analysis counts the number of 
turns in the signal, and compares that number with the amplitudes of the corresponding 
segments between two turns. Measurements were first performed at a fixed force level 
(loading with 2 kg), but it was later found that a force fixed relative to the subject’s 
maximum yielded superior results. The so-called turns-amplitude analysis at a force of 
30% of maximum and analysis of individual MUPs sampled at weak effort were 
compared in patients with a dystrophic myopathy. The two methods gave a similar 
diagnostic yield and supplemented each other.5  
    Analysis of turns-amplitude at a given force level is time consuming, and requires 
cooperation of the patient. Therefore, a method was developed which measures turns 
and amplitudes independent of force levels. A plot is made from the number of turns, on 
the x-axis, and the corresponding amplitudes, on the y-axis. Measurements are made at 
increasing levels of contraction. The distribution of 20 values from control subjects has 
been called ‘the cloud’.14 In myopathies, many points in the plot will be below this cloud, 
whereas points will be above and to the left in neurogenic disorders.  
    The turns-amplitude analysis using clouds proved a solid quantitative technique. In 
large study of consecutive, unselected patients with neuromuscular disease, turns-
amplitude analysis had superior sensitivity (75%) with unchanged specificity (85%) as 
compared to quantitative MUP analysis.12 Qualitative MUP assessment scored similarly 
to quantitative MUP analysis. This is one of the few studies that did not select a group of 
healthy volunteers and patients with a clear-cut myopathy or neuropathy to investigate, 
but rather a broad spectrum of affections. In another study, it was found that the turns-
amplitude analysis can give rise to false-negative findings, especially in the higher force 
levels.10
 
Other quantitative methods 
 
Macro-EMG was introduced to obtain a relative indication of the motor unit size. A special 
needle is used which records single fibre action potentials and motor unit potentials 
5. Introduction (II) 80 
simultaneously. Macro-EMG is best used to measure fibre density (the number of the 
fibres within the territory of a motor unit). When compared to other techniques, sensitivity 
is lowest for the macro-EMG MUP analysis.7
    The analysis of firing rates at higher force levels requires signal decomposition 
techniques. The use of these methods has not been investigated yet. 
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ABSTRACT 
 
We prospectively assessed diagnostic yield of muscle fiber conduction velocity (MFCV) 
studies in patients with signs and symptoms suggestive of a myopathy. Results were 
analysed with respect to the final diagnosis, and compared to the reference standard, 
which was qualitative electromyography (EMG), turns-amplitude analysis (TAA), and 
muscle biopsy. We included 125 patients, in whom a myopathy was diagnosed in 71, and 
a neuromuscular disorder was excluded in 54. Sensitivity of MFCV for the presence of a 
myopathy was 84%, and specificity 83%. Diagnostic yield of MFCV was superior to EMG, 
TAA, and muscle biopsy in patients with metabolic myopathies, non-dystrophic 
myopathies, and channelopathies. We concluded that measurement of MFCV is a 
quantitative EMG technique with a high diagnostic yield. In certain myopathies, MFCV 
may be more informative than conventional EMG examination. 
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INTRODUCTION 
 
Electromyography (EMG) is a core tool for the neurophysiologist in the diagnosis of  
myopathies. Qualitative assessment of EMG is especially of diagnostic value if the 
changes are clear-cut, the examiner is experienced, or both.11 However, considerable 
intra- and interobserver variation was reported.13 Quantitative techniques have the 
advantage to provide reproducible findings, but none of these techniques have proven to 
be superior to the usual qualitative assessment.11,14
    One of the quantitative EMG techniques available is the invasive measurement of 
muscle fibre conduction velocity (MFCV).1,18 Several authors have reported abnormal 
MFCV in myopathies.6,7,12,21  Since these studies concerned measurements in selected 
patients with a clear-cut myopathy, the overall diagnostic yield of MFCV measurements 
remained unclear. We previously reported, in a prospective study of patients with 
inflammatory myopathies, that MFCV can be complementary to EMG.1 We furthermore 
demonstrated that MFCV is related to fibre diameter in a linear fashion.3 This suggests 
that MFCV measurements can be used to detect  increased fibre diameter variability, 
which is often the first histological sign of a myopathy.  
    In the present prospective study, we assessed the diagnostic accuracy of MFCV 
measurements in patients with clinical signs and symptoms suggestive of a myopathy. 
The study was performed according to the STARD guidelines.4
 
METHODS 
 
Patients and control subjects 
During a study period of 4 years, MFCV measurements were obtained from patients who 
were referred to our laboratory by neurologists from the Neuromuscular Centre 
Nijmegen, a tertiary referral centre for patients with neuromuscular disorders. The 
medical records of these patients were reviewed for the following inclusion criteria: signs 
and symptoms suggestive of a myopathy at the time of referral; MFCV measurements 
performed during, but not included in, the diagnostic process; and the establishment of a 
final diagnosis of a myopathy, that fulfilled the international accepted criteria,10 or of a 
neuromuscular disease excluded. The definite diagnosis was established by the referring 
neurologist, independent of the present study. Diagnosis was based on clinical 
examination, time course of the disease, and results of additional investigations. These 
included laboratory investigations; neurography and EMG; and a muscle biopsy on 
indication. The final diagnosis was used as ‘golden standard’ for the present analysis. 
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    Normal MFCV values for our laboratory were obtained from 39 healthy volunteers (20 
women, 19 men, mean age 30 years, range 19-57 years). 
 
Diagnostic examinations 
Qualitative EMG examination, which was part of the diagnostic process, was done on a 
Synergy EMG system (Oxford Instruments, Surrey, United Kingdom) by an experienced 
clinical neurophysiologist from our department using a concentric needle electrode, 
according to established principles. Qualitative assessment included visual and auditory 
inspection of spontaneous muscle fibre discharges, motor unit potential (MUP) 
characteristics, and interference pattern characteristics. The conclusion of the 
examination was used for analysis in the present study. Borderline abnormal and 
inconclusive EMGs were considered non-diagnostic. 
    Quantitative EMG analysis included turns-amplitude analysis (TAA) independent from 
force measurements, obtained from the muscle in which MFCV was to be measured. At 
least 20 recording were obtained at different levels of force. The ‘clouds’ presented by 
the software of the Synergy EMG system were used as normal boundaries.15 TAA was 
considered to be myopathic if 15% or more of the points showed up below the cloud. 
    A needle muscle biopsy was performed on indication. Biopsies from the quadriceps or 
the brachial biceps muscle were obtained by a neurologist, and evaluated 
microscopically by a neuropathologist according to established principles. Routine 
staining included myosin adenosine-triphosphatase, succinate dehydrogenase, 
cytochrome oxidase, acid phosphatase, periodic acid-Schiff, Sudan black, trichrome 
stain, and histocompatibility-complex class I antigens. Additional measurements, such as 
complex I to IV activity, or electron microscopy were only performed on indication. The 
histopathological conclusion was used for analysis in the present study. Biopsies with 
minor non-specific abnormalities were considered non-diagnostic. 
    Informed consent was obtained at the time of the MFCV study. All MFCV 
measurements were performed by the first author of this report, who was not involved in 
the diagnostic process. The study was approved for by the Hospital Ethical Committee, 
and performed according to the Helsinki principles. 
 
MFCV 
The brachial biceps muscle was the preferred muscle to be studied. If signs and 
symptoms were present only in the lower extremities, measurements were performed in 
the quadriceps muscle. In a few cases with local symptoms, a different muscle was 
chosen. In the control population, measurements were obtained from the brachial biceps  
6. MFCV in myopathies 87
in 30 subjects, from the quadriceps muscle in 5 subjects, and from the brachioradial 
muscle in 4 subjects. 
    MFCV was measured using a the modified Troni method, as described in the 
introduction of the thesis.18,20 Cut-off values were set at 2 standard deviations (SD) above 
and below mean MFCV (2.9 to 4.5 m/s), and 1 SD above F/S ratio (below 2.2). 
 
 
 
TABLE 1. Final diagnosis of the included patients. 
Disorder No. Specified diagnose  
Dystrophic myopathy 15 Limb girdle myopathy 6 
  Myopathy with rods 3 
  Becker dystrophy 2 
  Dystrophic myotonia 2 
  Ocular pharyngeal muscular dystrophy 2 
Metabolic myopathy 9 Phosphorylase deficiency (Mc Ardle disease) 1 
  Acid maltase deficiency (Pompe disease) 3 
  Chronic progressive external opthalmoplegia 1 
  Mitochondrial myopathy 4 
Inflammatory myopathy 23 Polymyositis 13 
  Dermatomyositis 5 
  Inclusion body myositis 5 
Non-dystrophic myopathy  15 Steroid myopathy 3 
  Secondary myopathy* 5 
  Critical illness myopathy 1 
  Myopathy not classified£ 6 
Channelopathy 9 Periodic paralysis 4 
  Paramyotonia 4 
  Andersen syndrome 1 
All myopathies 71   
No myopathy 54   
*Secondary myopathy consists of myopathies associated with CREST syndrome, (1), 
sarcoidosis (1), Ehlers Danlos disease (1), autoimmune polyglandular syndrome (1), and 
alcoholism (1). 
£In these patients, a definite diagnosis could not be established. Myopathic abnormalities on 
clinical examination, or EMG, or muscle biopsy, were present. 
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Statistical analysis 
Sensitivity, specificity, positive and negative predictive values for a dichotomous 
diagnostic decision were determined for MFCV, EMG, TAA, and muscle biopsy, with the 
final diagnosis as reference standard. A receiver operating curve was compiled from the 
F/S ratio. One-way non-parametric ANOVA (Dunn’s multiple comparison test) was used 
to compare MFCV results between the myopathies groups, the group of patients with no 
neuromuscular disorder, and the control group. 
 
RESULTS 
 
MFCV studies were obtained from 131 patients (69 females, 62 males), who met the 
inclusion criteria of this study. Six studies were excluded, because of technical issues. 
Ninety-eight studies were obtained from the brachial biceps muscle, 15 from the medial 
vastus muscle, 8 from the lateral vastus muscle, and 4 from the brachioradial muscle. 
    A definite myopathy was established in 71 of 125 patients (Table 1). In 54 patients, a 
myopathy or any other neuromuscular disorder could be excluded. Many of these 
patients complained of fatigue, muscle cramps, or muscle stiffness, often exercise 
related. A sub-group of these patients had a systemic connective tissue disease and 
concomitant muscle complaints. In a few cases, a slightly elevated creatine kinase was 
the reason for referral.  
 
 
TABLE 2. Results of MFCV studies. 
diagnosis 
# of 
patients 
Mean MFCV 
(m/s) ± SD F/S ratio ± SD 
Mean # fibres 
per study ± SD 
Dystrophic myopathy 15 3.6 ± 1.0 4.5 ± 3.3* 42 ± 14§
Metabolic myopathy 9 3.5 ± 0.4 3.0 ± 0.9* 35 ± 10 
Inflammatory myopathy 23 2.9 ± 0.5* 3.6 ± 1.6* 56 ± 20* 
Non-dystrophic myopathy  15 3.6 ± 0.7 3.8 ± 1.7* 44 ± 16§
Channelopathy 9 3.0 ± 0.5 2.5 ± 0.9 31 ± 11 
All myopathies 71 3.3 ± 0.8* 3.7 ± 2.1* 42 ± 18§
No myopathy 54 3.6 ± 0.5 1.7 ± 0.3 29 ± 8 
Controls 39 3.7 ± 0.4 1.7 ± 0.4 29 ± 8 
* significantly different (p<0.001) from controls 
§ significantly different (p<0.05) from controls    
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    The results of the MFCV measurements are presented in Table 2. For the complete 
sample of patients with a definite myopathy, mean MFCV, F/S ratio and numbers of 
fibres per study were significantly different both from the healthy controls, and from the 
group with no neuromuscular disorder. More specifically, mean MFCV was significantly 
lower in the inflammatory myopathies, and lower, albeit not significantly, in the 
channelopathies. F/S ratio was significantly higher in all groups but the channelopathies. 
A conduction velocity histogram, illustrating distribution of velocities, was generated from 
all fibres of the various myopathies group (Figure 1). 
    Mean MFCV was abnormal in 23 out of 71 tests in the patients with a myopathy, and 
F/S ratio was abnormal in 57 tests. In contrast, mean MFCV was abnormal in 2 out of 54 
tests in those with no neuromuscular disorder, and F/S ratio was abnormal in 8. Thus, 
F/S ratio was the most informative  parameter of the test. A receiver operating curve was 
compiled for F/S ratio (Figure 2). Based on this figure, the previously defined cut-off value 
for F/S ratio (2.2) was not changed. 
 
 
 
 
 
 
 
FIGURE 1. MFCV histograms of all 
disease groups. The distribution of the 
controls (lower left panel) is projected in 
grey in each histogram. 
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TABLE 3. Diagnostic accuracy of MFCV, EMG, TAA, and muscle biopsy. 
 Sensitivity (%) Specificity (%) PPV NPV 
MFCV 84 83 0.88 0.79 
Qualitative EMG 79 75 0.77 0.73 
TAA 44 85 0.77 0.57 
Muscle biopsy 68 100 1.00 0.63 
 
 
    Diagnostic accuracy for all tests is shown in Table 3, and sensitivities of the tests for 
each group of patients in Table 4. Overall, diagnostic accuracy of MFCV was superior to 
that of conventional EMG. Specifically, MFCV was superior to EMG and muscle biopsy in 
detecting abnormalities in the metabolic and non-dystrophic myopathies, whereas EMG 
was superior to MFCV in dystrophic and inflammatory myopathies. In channelopathies, 
the diagnostic yield of MFCV was higher than of conventional EMG, while muscle 
biopsies were not obtained from these patients. The diagnostic yield of TAA analysis was 
lowest in all groups. Non-specific abnormalities were found in muscle biopsies of 6 
patients with a specific myopathy, and in 10 patients in whom a neuromuscular disorder 
could be excluded. 
 
 
 
FIGURE 2. Receiver operating 
curve for the F/S ratio. The cut-
off values for F/S ratio can be 
varied to enhance sensitivity or 
specificity. 
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TABLE 4. Sensitivity of MFCV, EMG, TAA and muscle biopsy for the myopathies groups. 
 MFCV Qualitative EMG TAA Muscle biopsy 
 Sensitivity (no. 
of studies) 
Sensitivity (no. 
of studies) 
Sensitivity (no. 
of studies) 
Sensitivity (no. 
of studies) 
Dystrophic 
myopathy 
80% (15) 92% (14) 50% (12) 91% (11) 
Metabolic 
myopathy 
91% (9) 33% (9) 43% (7) 43% (7) 
Inflammatory 
myopathy 
87% (23) 98% (23) 56% (18) 76% (21) 
Non-dystrophic 
myopathy 
87% (15) 80% (15) 42% (12) 45% (11) 
Channelopathy 78% (9) 56% (9) 0% (5) 0% (0) 
All myopathies 85% (71) 78% (70) 44% (54) 68% (50) 
   
 
DISCUSSION 
 
Measurement of  MFCV is a quantitative EMG technique with a high diagnostic accuracy 
for myopathies. In our study, the technique was superior to needle EMG in the diagnosis 
of metabolic myopathies, non-dystrophic myopathies, and channelopathies, but not in 
dystrophic and inflammatory myopathies. 
    Noticably, sensitivity and specificity for EMG, TAA and muscle biopsy were very likely 
overestimated in our study, because the results of these examinations were taken into 
account when reaching the final diagnosis. However, the aim of this study was not to 
assess diagnostic accuracy of EMG, TAA, and biopsy. Although our results are in 
concordance with those previously reported, the literature on diagnostic yield of 
conventional EMG and muscle biopsy in myopathies is surprisingly sparse.1,5,14
 
    Needle EMG can be performed quickly in a routine setting, and most muscles are 
available for examination. A MFCV study usually takes about 15 minutes to perform, and 
can be done in any laboratory, provided that a single fibre EMG stimulating electrode and 
an EMG device are present. Many muscles can be measured, although normal values 
should be obtained for each muscle individually. 
    Several potential explanations for the difference in diagnostic accuracy between MFCV 
and EMG can be considered. First, the morphology of a MUP, as recorded with a 
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concentric needle electrode, is strongly influenced by the distance of the activated fibres 
to the tip of the needle,17 and by the distance from the endplate to the point of the 
sarcolemma where the needle is recording. In contrast, during MFCV measurements, 
fibres are stimulated and recorded within one or a few fascicle(s), thus reducing variation 
in signal morphology due to spatial factors. 
    Second, since MUPs can only be assessed individually at low force levels, estimates 
of motor unit size are biased by type I units. MFCV measurements are made independent 
of voluntary contraction, and therefore get round the bias of selective motor unit 
assessment. 
    Third, it has been demonstrated that, whereas the fibre diameter range is often 
increased in myopathies, conventional EMG is not very sensitive to an increase of this 
variability. In a computer model that generates MUPs, an increase of the SD of mean 
fibre diameter from 10 μm (which is normal) to 30 μm (which is pathological) resulted in a 
significant increase of only the number of turns and phases of a MUP, while the routinely 
more important parameters, such as duration and amplitude, did not change.16 In 
contrast, and in line with the linear relation between MFCV and fibre diameter as 
previously shown,3 the results of the present study confirm that measurement of MFCV is 
a sensitive technique to detect fibre diameter abnormalities. Particularly, the F/S ratio is 
sensitive to diameter changes, while it takes many abnormal fibres to reduce mean 
MFCV to below the cut-off value. However, it should be noted that fibre diameter is 
abnormal in neurogenic disorders as well. As such, MFCV cannot discriminate between 
atrophy due to myopathy, atrophy due to denervation, or the presence of small fibres due 
to regeneration. 
    Disturbed conduction velocity can also be caused by abnormal sarcolemmal 
propagation of action potentials.8,9,19 In most channelopathies, mutant and wildtype 
channels are distributed diffusely among fibres. Propagation is therefore generalised 
slowed down, because less or less functional ion channels are available in each fibre. 
This explains the lower mean MFCV found in this group. Noticably, in some 
channelopathies, typical myotonic EMG discharges are not found interictally. EMG is 
often normal, interictally, in channelopathies as well. MFCV however is disturbed, both 
interictally and ictally. 
    Mean MFCV was significantly lower in the inflammatory myopathies group. Although 
fibre atrophy is often extensive in these myopathies, it is usually not more severe than in 
dystrophic myopathies. Low mean MFCV therefore suggests that sarcolemmal 
dysfunction further contributed to slowing of propagation. The spontaneous muscle fibre 
discharges, as frequently found in these patients, also indicate sarcolemmal instability.2
6. MFCV in myopathies 93
    Finally, the subjective character of conventional EMG assessment gives rise to 
interobserver variation.13 In contrast, MFCV measurements are of a quantitative nature, 
strongly reducing intra- and interobserver variation. Pearson measurement-
remeasurement coefficients of 0.88 for mean MFCV and 0.78 for F/S ratio have been 
reported.20
    Nirkko et al. reported a sensitivity of 74% and a sensitivity of 80% for TAA as another 
quantitative technique in the diagnosis of myopathies.14 They demonstrated that 
quantitative analysis of the interference pattern was superior to quantitative and 
qualitative MUP assessment. On these grounds, we selected TAA for  quantitative EMG 
examination in this study. Our results for EMG and TAA were similar to those previously 
reported, showing a slightly lower sensitivity for TAA, and a slightly higher specificity for 
EMG.14
 
   Our data suggests that, as a rule of thumb, low mean MFCV with high F/S ratio is 
indicative of an inflammatory myopathy, whereas low mean MFCV with marginally 
increased F/S ratio is indicative of a channelopathy. We did not find any other specific 
MFCV pattern related to a particular kind of  myopathy. This is not different from a 
myopathic EMG pattern, which is also highly unspecific. Even neurogenic or a “mixed” 
can be found in many myopathies.11 A muscle biopsy may provide more specific findings, 
such as inflammatory changes, or central cores. Nevertheless, non-specific biopsy 
results were reported in 20% of patients with a definite myopathy,5 and were found in 
13% in our study. In addition, a muscle biopsy has the practical disadvantage that it is 
liable to a sampling error, and that only a few muscles are easily accessible. 
    The drawbacks of the technique of invasive MFCV measurements should also be 
considered. There is uncertainty about the distance between the stimulating and 
recording electrodes, which may especially be a problem if fibres run skew with respect 
to the needle insertion sites. The relatively long distance of 50 mm between stimulating 
and recording electrodes reduces this effect however sufficiently. Also, an error of up to 
8% may be induced if the electrodes are not inserted perpendicular to the skin.20 
Furthermore, nerve twigs may be stimulated instead of muscle fibres. This evokes a 
potential with a different morphology, usually preceding the direct fibre responses. It will 
also invariably cause a gross muscle twitch, which can be used to make the distinction 
with direct muscle fibre responses.18 Muscle fibre jitter, larger when nerve twigs are 
stimulated, can also be measured to verify the origin of the response. 
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    We conclude that MFCV measurement is a viable quantitative EMG technique that can 
be easily performed in every day clinical practice, and is superior to needle EMG in the 
diagnosis of metabolic myopathies, non-dystrophic myopathies, and channelopathies. 
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ABSTRACT 
 
We prospectively investigated whether early diagnosis of amyotrophic lateral sclerosis 
(ALS) could be facilitated by demonstrating signs of denervation in a muscle of a clinical 
and electromyographical unaffected region. Muscle fibre conduction velocity (MFCV) was 
determined in 18 patients in whom the diagnosis ALS was considered but not established 
beyond a level of clinically possible ALS according to the revised El Escorial criteria. A 
muscle biopsy was obtained from the same muscle, to demonstrate neurogenic changes. 
The study followed the guidelines from the STARD initiative. Results were analysed with 
respect to the final diagnosis. After a mean follow-up of 16 months, 9 patients developed 
probable or definite ALS.  Sensitivity of abnormal MFCV for developing ALS was 89%. 
Muscle biopsy confirmed that denervation was the cause of abnormal MFCV. We 
concluded that MFCV can be used to detect denervation in muscles that show no clinical 
or electromyographical signs of lower motor neuron disease, and thus may contribute to 
early diagnosis of probable laboratory-supported ALS. 
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INTRODUCTION 
 
Needle electromyography (nEMG) can be an important contributor to early diagnosis of 
amyotrophic lateral sclerosis (ALS). Fibrillation potentials, positive waves, and abnormal 
motor unit potentials may indicate lower motor neuron (LMN) dysfunction prior to 
weakness or muscle atrophy.1,2 According to the revised El Escorial criteria, such 
findings may lift the diagnosis from clinically possible ALS to clinically probably 
laboratory-supported ALS.3 A clear definition of the stage of the disease is desirable for 
good clinical practice, and mandatory for research purposes. Nevertheless, in some 
patients with clinical signs or symptoms of possible ALS, evidence for LMN or upper 
motor neuron (UMN) disease in other regions cannot be found. These patients are faced 
with a period of uncertainty, because a diagnosis of ALS, or any other disorder, is usually 
only established after time has elapsed. In some of these patients, there is a need for a 
diagnostic technique that is capable of detecting changes in muscle tissue due to LMN 
disease, even before needle EMG can. Measurement of muscle fibre conduction velocity 
(MFCV) may be such an EMG technique. Increased fibre diameter variability can be an 
early sign of denervation,4 MFCV is related to fibre diameter in a linear fashion.5 and 
abnormal MFCV in muscles affected by motor neuron degeneration has been reported 
before.6
    In the present study, we prospectively estimated the diagnostic accuracy of MFCV in 
patients with possible ALS, or unexplained LMN symptoms. Measurements were made in 
a region that was clinically unaffected, and showed no nEMG signs of denervation. 
Muscle biopsies were obtained from the same muscle to verify the origin of abnormal 
findings. This study used the guidelines from the STARD initiative for studies on 
diagnostic techniques.7
 
METHODS 
 
Patients were recruited from the Neuromuscular Centre Nijmegen, which is a secondary 
referral centre for patients with motor neuron disease. During a study period of 3 years, 
patients were consecutively included if they fulfilled the revised El Escorial (Airlie House) 
criteria of possible ALS, or if the underlying cause of LMN dysfunction in one or two 
regions could not be identified and ALS was considered. Clinically possible ALS was 
defined when clinical signs of UMN and LMN dysfunction were found together in only one 
region, or UMN signs were found alone in two or more regions; or LMN signs were found 
rostral to UMN signs and the diagnosis of clinically probable laboratory-supported ALS 
7. Early diagnosis of ALS 102 
could not be proven by evidence on clinical grounds in conjunction with neurophysiologic, 
neuroimaging or clinical laboratory studies. Patients with a pure LMN syndrome in one or 
two regions were included if progressive muscle atrophy was present in at least 2 
muscles, muscles not innervated by the same nerve or root, and in whom a diagnosis 
could not be established on clinical grounds in conjunction with neurophysiologic and 
neuroimaging studies.  
    Approximately 250 ALS patients were seen during the study period, and approximately 
7% of these met the inclusion criteria of this study. Informed consent was asked before 
inclusion, and the study was carried out according to the Helsinki Principles.  
    Prior to inclusion, diagnostic needle EMG was performed according to established 
principles,  by an experienced neurophysiologist. In the region that was to be studied, 
spontaneous muscle fibre discharges were absent, and motor unit potentials and 
interference pattern characteristics were within normal limits. 
    MFCV was obtained from a proximal muscle in a region that was clinically unaffected, 
and showed no evidence of LMN disease by nEMG examination. Thus, the quadriceps 
muscle was examined if the patient had UMN or LMN signs in an upper extremity, while 
the brachial biceps muscle was examined if the patient had UMN or LMN signs in a lower 
extremity. MFCV measurements were performed by the first author, who had not 
participated in the clinical and EMG examination prior to inclusion. MFCV was measured 
using the modified Troni technique, as described in the introduction of this  thesis.8,9 
Cutoff values were set at 2 SD below normal for mean MFCV (> 2.8 m/s), and 2 SD 
above normal for the F/S ratio (< 2.2). 
    Following MFCV measurements, a needle muscle biopsy was obtained from the same 
muscle, and evaluated microscopically by a neuropathologist according to established 
principles. Muscle changes indicative of denervation were angular atrophic fibres of both 
fibre types, possibly combined with hypertrophic fibres with an increased number of 
internal nuclei. Fibre type grouping was considered a sign of reinnervation. Non-specific 
abnormalities included scattered fibre hypertrophy with internal nuclei but without 
atrophy, the presence of a small number of necrotic fibres, and normal fibre diameters 
but other non-specific abnormal findings such as increased subsarcolemmal 
mitochondrial activity. 
    The follow-up period was at least 1 year. During the follow-up, patients were regularly 
seen by their neurologist, until a final diagnosis of ALS, or a different disorder could be 
established. The final diagnosis was based on consecutive clinical examinations, and 
repeated additional investigations, such as neuroimaging and EMG, excluding MFCV 
and biopsy results. 
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    Sensitivity, specificity, positive and negative predictive values for a dichotomous 
diagnostic decision of ALS or no ALS, were determined for MFCV and for the muscle 
biopsy. A final diagnosis of ALS was defined as fulfilling the revised El Escorial criteria for 
clinically probable, probable laboratory-supported, or definite ALS. 
 
RESULTS 
 
Eighteen patients were included: 10 with possible ALS, and 8 with LMN signs of 
unidentified cause in one or two regions. Clinical signs and symptoms, time from onset to 
presentation, and follow-up period after presentation are shown in Table 1. Eleven 
patients were male (mean age, 58 years; SD 10 years), and 7 female (mean age, 60 
years; SD, 11 years). Nine studies of MFCV and biopsy were obtained from the 
quadriceps muscle, and 9 studies from the brachial biceps muscle. Mean time from onset 
to presentation was 23 months (range: 5-75), mean follow-up period was 16 months 
(range: 12-25). A final diagnosis of ALS was established in 9 patients (2 definite ALS, 4 
probable ALS, 2 probable laboratory-supported ALS, and 1 UMN-dominant ALS). Two of 
these 9 patients died from ALS-related complications during the follow-up period. The 
final diagnosis of the patients who did not develop ALS are also shown in Table 1. In one 
patient with a positive family history for ALS, the cause of his cramps and fasciculations 
of the legs remained unidentified. This patient also suffered from restless legs syndrome. 
     
    Diagnostic accuracy of MFCV and muscle biopsy are shown in Table 2. Abnormal 
MFCV was found in 8 patients developing ALS, and in 3 patients of the non-ALS group (2 
patients with primary lateral sclerosis, and 1 patient with a cervical radiculopathy). 
Denervation in the muscle biopsy was found in 7 patients developing ALS, and non-
specific findings in the remaining 2 patients. Denervation was also seen in 1 patient of 
the non-ALS group (the patient with monomelic amyotrophy). Signs of reinnervation were 
found in 2 patients, 1 of whom developed probable laboratory-supported ALS. 
    Mean MFCV of the ALS group was 3.3 (SD 0.3 m/s), and of the non-ALS group 3.4 
(SD 0.6 m/s), the difference being not significant. F/S ratio was 3.6 (SD 1.8) in the ALS 
group, and 2.6 (SD 1.6) in the non-ALS group, the difference being not significant. A 
specific pattern of abnormal conduction velocities on which the ALS and non-ALS groups 
could be discriminated was not found, although fibres tended to have slower MFCV in the 
ALS-group (Figure 1). 
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TABLE 1.  Patient characteristics. 
 
 
 
 
Age, 
sex 
Symptoms at 
presentation 
Time from 
onset to 
inclusion 
(months) 
Follow-up 
(months) Final diagnosis 
1 45, f LMN arm + UMN leg 40 20 Definite ALS 
2 64, f LMN legs 16 20 Definite ALS 
3 61, m LMN bulbair, UMN arm 30 12 Probable ALS 
4 70, f LMN legs, UMN arm 14 12 Probable ALS 
5 64, f LMN + UMN legs 11 15 Probable ALS 
6 50, f LMN + UMN leg 12 24 Probable ALS – lab sup 
7 71, m LMN leg + UMN arm 5 12 Probable ALS 
8 67, m LMN + UMN leg 12 14 Probable ALS – lab sup 
9 66, m LMN + UMN legs 24 12 UMN dominant ALS 
10 65, m LMN legs, ALS in family 13 17 LMN of unidentified cause 
11 75, f LMN arm 14 24 Monomelic amyotrophy  
12 60, m UMN arms and leg 48 12 Primary lateral sclerosis 
13 50, f UMN + LMN legs 45 15 Primary lateral sclerosis + 
inclusion body myositis 
(biopsy proven) 
14 56, m LMN arm, generalized 
fasciculations 
9 25 Cervical radiculopathy 
15 61, m LMN arm 24 10 Cervical radiculopathy  
16 47, m LMN both arms, UMN leg 75 10 Cervical myelopathy with 
bilateral amytrophic diplegia 
17 51, m LMN arm 7 21 Chronic progressive 
plexopathy 
18 35, m LMN legs, ALS in family 26 10 Restless legs syndrome 
 
 
TABLE 2.. Diagnostic accuracy for MFCV and muscle biopsy for the diagnosis of probable, 
probable laboratory-supported, or definite ALS. 
 Sensitivity Specificity 
Positive predictive 
value 
Negative predictive 
value 
MFCV 89% 56% 0.66 0.83 
Muscle Biopsy 78% 89% 0.88 0.80 
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FIGURE 1. Histogram of conduction velocities of the patients developing ALS, the patients 
not developing ALS, and the control population (scaled to fit). A wide range of conduction 
velocities was found in both patient groups. 
 
 
DISCUSSION 
 
This study demonstrates that increased fibre diameter variability may indicate LMN 
dysfunction prior to muscle weakness, atrophy, or nEMG abnormalities in patients who 
eventually will develop ALS. 
    The patients included in this study represent a small but difficult group of patients who 
are referred to our clinic. In most patients, a diagnosis of ALS, or any other neurological 
disorder, can usually be established after the first diagnostic work-up. This process can 
be frustrated however, by normal or inconclusive results from EMG and neuroimaging, 
especially if disease progression is slow. It is in these patients that MFCV studies may 
prove useful. Given the high negative predictive value, probable ALS is unlikely to 
develop if MFCV is normal. In such a case, other, possibly less devastating or even 
treatable disorders should be considered, such as cervical myelopathy, monomelic 
amyotrophy, or radiculopathy. Abnormal MFCV, when found in a clinical and 
electromyographical normal muscle in a patient in whom the diagnosis of ALS is 
considered, should be regarded as evidence for a more widespread disease. In such a 
case, a muscle biopsy of the same muscle may be obtained to identify the cause of 
abnormal propagation velocity. If the biopsy findings are consistent with a progressive 
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neurogenic disorder, the patient should be regarded as having probable laboratory-
supported ALS, and treated as such. 
    Slowing of propagation has been described in myopathies as well as in neurogenic 
disorders.5,6,8 The slowly conducting fibres relate to atrophic fibres mainly, either due to 
denervation or due to myopathy, and may also represent early regenerating fibres. We 
also measured fast conducting fibres in both groups (Figure 1), which very likely relate to 
large fibres, either due to neurogenic or (secondary) myopathic hypertrophy. A bimodal 
pattern of low and high conduction velocities, similar as to that of diameters in neurogenic 
disease, was not found. This suits the idea that the LMN disease was still in an early 
stage, before extensive reinnervation had taken place. The lack of specificity of slow or 
fast MFCV is a drawback of the technique. 
    In this regard, morphological data can be more specific. This was illustrated by the 
inflammatory signs found in the patient with inclusion body myositis, a disorder which 
should be recognized as an important mimic of ALS.10,11
    Our data confirms the notion that muscle fibre diameter pathology needs to be rather 
severe before it is reflected in the motor unit action potential, as recorded with nEMG. A 
computer model that generates motor unit action potentials, predicted that an increase of 
the standard deviation of mean fibre diameter from 10 μm (which is normal) to 30 μm 
(which is pathological) resulted in a significant increase only of the number of turns and 
phases, but not of important parameters, such as amplitude and duration.12 This 
implicates that nEMG is not a sensitive technique to detect changes in muscle, if these 
are only light to moderate. Given the subjective nature of routine nEMG investigations, it 
was stated that nEMG is especially of diagnostic value if the changes are clear-cut, the 
examiner experienced, or both.13
 
    Although the El Escorial diagnostic criteria have been developed primarily for research 
purposes, good clinical practice also requires a clear definition of the stages of a disease. 
An accurate diagnosis of ALS in an early stage of the disease is important in the context 
of clinical trials, as well as for the recognition of disorders that may masquerade as ALS. 
Indeed, the application of the criteria may facilitate early recognition of non-ALS 
disorders in patients classified as possible ALS.11 Our study suggests that in those 
patients in whom the normal work-up, including EMG, does not lift the diagnosis beyond 
possible ALS, further studies including MFCV and possibly muscle biopsy of an 
unaffected region can be performed to search for signs of denervation. 
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ABSTRACT 
 
Combinations of different techniques can increase the diagnostic yield from 
neurophysiologic examination of muscle. In 25 patients with suspected inflammatory 
myopathy, we prospectively performed needle electromyography (EMG) and measured 
muscle fibre conduction velocity (MFCV) in a single muscle, using a technique with direct 
muscle fibre stimulation and recording. Results of MFCV were compared with final 
diagnosis, EMG, and needle muscle biopsy. Diagnostic accuracy of combined MFCV and 
EMG studies was 72%, compared to 60% for EMG alone. This improvement was due to 
a gain in specificity. The MFCV did not prove useful in discriminating inflammatory 
myopathy from other myopathies. Furthermore, we found a correlation of 92% between 
variability of MFCV and myopathic changes in muscle biopsy. We conclude that the utility 
of electrodiagnostic examination can be increased if EMG examination is combined with 
MFCV studies. 
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INTRODUCTION 
 
The sensitivity of needle electromyography (EMG) in the diagnosis of neuromuscular 
disease is high, but false positive findings are not uncommon.3 This is in part due to the 
subjective character of assessment giving rise to interobserver variability. Currently, the 
sensitivity of EMG for the diagnosis inflammatory myopathy is 80-90%, although this 
figure may vary at different stages of the disease and between muscles.3,6 The specificity 
of EMG for the diagnosis of inflammatory myopathy is not described in the literature. 
    As suggested by Liguori et al., improvement of diagnostic yield and specificity can be 
achieved by combining different techniques.8 One of these is the measurement of muscle 
fibre conduction velocity (MFCV). Several investigators have addressed the issue of 
measuring the propagation velocity along muscle fibres, and both invasive and non-
invasive techniques have been developed.1,2,10,14 Muscle fibre diameter and sarcolemmal 
excitability are factors influencing MFCV, and both are affected in inflammatory 
myopathy. However, the value of performing MFCV measurements in patients suspected 
of inflammatory myopathy has not been investigated. 
    We studied the value of MFCV studies in the diagnostic work-up of patients presenting 
with clinical signs and symptoms suggestive of inflammatory myopathy. MFCV was 
assessed by means of an invasive technique with direct muscle fibre stimulation. This 
technique has been validated, is easy to perform, and produces objective and 
quantitative results.4,15  
 
METHODS 
 
Patients and controls 
All patients presenting in 1999 at our institution with clinical signs and symptoms 
suggestive of inflammatory myopathy were included. They were seen by a neurologist 
with neuromuscular expertise, and underwent a detailed clinical examination. Additional 
investigation included determination of serum creatine kinase, thyroid hormones, 
erythrocyte sedimentation rate, leukocyte count and liver enzymes; electrodiagnostic 
evaluation; and a Bergström needle muscle biopsy. Established criteria were used for 
diagnosing inflammatory myopathy.5,16
    Twenty-four healthy individuals (15 women, 9 men; mean age 30 years (range 22-54)) 
served as a control group. 
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Electrodiagnostic evaluation  
Electrodiagnostic evaluation, including nerve conduction studies, needle EMG, and 
MFCV, was performed in our laboratory by a trained neurophysiologist on a Synergy 
system (Oxford Instruments, Surrey, United Kingdom). Several muscles were 
investigated, and in each muscle at least 5 sites were studied. Motor unit action 
potentials (MUPs) and interference pattern were evaluated subjectively and objectively 
with turns-amplitude analysis. The presence of spontaneous activity, such as fibrillation 
potentials and positive sharp waves, was noted, as was the appearance of complex 
repetitive discharges. 
    The EMG was regarded as typical for myositis if MUPs showed polyphasia and 
marked reduction in duration (<8 ms) and height (<1000 μV) in more than two muscles, 
and spontaneous activity occurred in two or more muscles (6, 13). The presence of 
complex repetitive discharges was not required.  
 
Muscle fibre conduction velocity measurement 
MFCV was measured according to the modified Troni method as described in the 
introduction of the thesis. The m.biceps brachii, m.vastus lateralis and m.vastus medialis 
were used, depending on the site of the muscle biopsy. 
 
Muscle Biopsy 
A needle biopsy of the m.biceps brachii or m.quadriceps was performed following the 
electrodiagnostic evaluation and MFCV examinations. If the same muscle was used, care 
was taken to insert the biopsy needle at a site between the points of stimulation and 
recording used in determining the MFCV. Muscle tissue was frozen in isopentane, 
processed immediately, and evaluated microscopically. Any abnormalities of the muscle 
fibres (including internal nuclei, fibre splitting, basophilic vacuoles, necrosis and type 
grouping) were noted. Fibre diameter range was measured manually for type I and type II 
fibres in sections stained with myosin adenine-triphosphatase (after incubation at pH 
4.2). Other sections were stained with succinate dehydrogenase, cytochrome oxidase, 
acid phosphatase, periodic acid-Schiff, Sudan black and trichrome stain. 
Immunohistochemical expression and others signs of an inflammatory response, such as 
cellular infiltration, were reported. 
    Changes in muscle tissue regarded as diagnostic of myositis included fibre-diameter 
variation with atrophic fibres, sarcolemmal expression of major-histocompatibility-
complex class I antigens, mononuclear cellular infiltrates (in polymyositis and inclusion-
body myositis also invading non-atrophic fibres), perifascicular atrophy of fibres (in 
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dermatomyositis), and other myopathic changes (necrosis, basophilic vacuoles, fibre 
splitting, fat, lobulated fibres, internal nuclei). Rimmed basophilic vacuoles were 
considered specific for inclusion-body myositis. 
 
Statistical Analysis 
Sensitivity, specificity, and accuracy were determined with respect to the diagnostic entity 
of idiopathic inflammatory myopathy.  For the distribution of fibre conduction velocities, 
kurtosis (k) was calculated. 
 
RESULTS 
 
Patients 
A total of 27 patients were included. Two patients were excluded because we could not 
obtain sufficient muscle fibre potentials for MFCV calculation. Thirteen patients were 
diagnosed with inflammatory myopathy (7 polymyositis, 3 dermatomyositis, 3 inclusion-
body myositis) and 6 patients with non-inflammatory myopathy (2 steroid myopathy, 1 
McArdle disease, 1 limb-girdle dystrophy, 2 non-specified myopathies). In 6 patients, no 
neuromuscular disease was diagnosed. 
 
Diagnostic Evaluation 
The averages of individual mean MFCV and F/S ratio in our patient population are given 
in Table 1. 
 
 
TABLE 1. Averages of individual mean MFCVs and F/S ratios for the patient groups.* 
    Velocity of 
 
Groups 
No. Of 
subjects 
Mean MFCV 
(m/s) F/S ratio 
Slowest 
fibre (m/s) 
Fastest 
fibre (m/s) 
Healthy controls 24 3.6 (±0.4) 1.5 (±0.3) 1.9 6.4 
Inflammatory myopathy 13 2.9  (±0.5) 2.8  (±2.2) 0.7 8.3 
Non-inflammatory 
myopathy 
6 3.3  (±0.8) 3.5  (±0.5) 1.1 9.5 
No neuromuscular 
disease 
6 3.4  (±0.5) 1.9  (±0.6) 1.3 5.4 
* Values are mean ± SD. Slowest and fastest fibre is for all fibres of the group. 
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   TABLE 2. Sensitivity, specificity, and diagnostic accuracy of EMG, MFCV studies, and 
combined investigations for the diagnosis of inflammatory myopathy. 
Investigation Sensitivity (%) Specificity (%) Diagnostic accuracy (%) 
EMG 85 33 60 
MFCV 77 42 60 
EMG plus MFCV 77 67 72 
 
 
    In general, mean MFCV was decreased in patients with inflammatory myopathy, 
leading to below-normal values in 7 of 13 patients, and F/S ratio was above normal in 9 
patients. Slowing was less pronounced in patients with non-inflammatory myopathy; 
abnormal values of mean MFCV were obtained in 2 of 6 patients, whereas the F/S ratio 
was abnormal in all 6. Mean MFCV and F/S ratio did not differ between patients with 
polymyositis, dermatomyositis, or inclusion-body myositis. An example of a typical 
recording in a patient with inflammatory myopathy is shown in Figure 1. 
    Eleven of the 13 patients, who were eventually diagnosed with myositis, had an 
abnormal EMG. Of these 11 patients, MFCV examination was abnormal in 10. Both 
myositis patients with a normal EMG had a normal MFCV examination. Of the 6 patients 
with a non-inflammatory myopathy, 4 had an abnormal EMG. The MFCV examination 
was abnormal in 3 of these 4 patients. Both patients with a non-inflammatory myopathy 
and a normal EMG had an abnormal MFCV examination. Four of the 6 patients with no 
neuromuscular disorder had an abnormal EMG. Three of these 4 had a normal MFCV 
examination. One patient with no neuromuscular disorder and a normal EMG had an 
 
FIGURE 1.  MFCV measurements in 
a myositis patient. Five sequential 
recordings at 1 Hz stimulus-interval, 
superimposed. Markers L1 and L2 
indicate latencies of fastest and 
slowest fibres; distance of stimulus to 
recording electrode equals 50 mm. 
Several slower spikes follow the 
normal complex of multiple spikes. 
MFVC ranges from 4.0 m/s (L1) to 
1.5 m/s (L2).  
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abnormal MFCV examination. Sensitivity, specificity, and diagnostic accuracy of EMG, 
MFCV studies, and combined investigations for the diagnosis of inflammatory myopathy 
are given in Table 2.  
    We found a correlation of 92% between the presence or absence of an above normal 
F/S ratio and myopathic or inflammatory changes in the muscle biopsy specimen. This 
correlation was present in all patient groups. For mean MFCV, this correlation was 76%, 
and for EMG it was 68%. There was no correlation of conduction velocities with specific 
characteristics of inflammation in the muscle biopsy, or with serum creatine kinase levels. 
 
DISCUSSION 
 
Our data indicate that EMG and MFCV examinations are complementary in the 
electrodiagnostic assessment of patients with suspected inflammatory myopathy. The 
inclusion of MFCV studies raised the diagnostic accuracy by 12%.  There are several 
potential explanations for the difference in diagnostic accuracy between EMG and MFCV 
examination. 
    Firstly, the low specificity of needle EMG can partly be explained by the high variation 
in the morphology of the MUP, caused by the small recording area of the concentric 
needle electrode, and the large influence of spatial and temporal distribution of muscle 
fibre action potentials.12 The variation in spatial distribution, as compared to EMG, is 
small in MFCV examinations because fibres are stimulated and recorded within one or a 
few fascicle(s), and within a close distance of the stimulating and recording electrode. 
Thus, the morphology of the recorded complex of spikes is influenced primarily by the 
difference in propagation velocities of individual muscle fibres. 
    Secondly, an increase in variability of muscle fibre diameter can be an early sign of 
myopathic disease. With needle EMG, increased variability in fibre diameter can be 
difficult to detect. In a computer model that generates MUPs, an increase of the standard 
deviation of the mean fibre diameter from 10 μm (which is normal) to 30 μm (which is 
pathological) resulted in a significant increase only of the number of turns and phases of 
a MUP.11 Other parameters, such as amplitude and duration, did not change.  
    As propagation of an action potential along the sarcolemma is a function of fibre 
diameter, increased variability in diameter will cause changes in MFCV.7,9 Our results 
show that the F/S ratio, indicating scatter of velocities, is a sensitive parameter for 
detecting myopathic changes, as the F/S ratio was increased in 15 of 19 patients with 
myopathic disease. This is further supported by the high correlation of F/S ratio and 
histological abnormalities, although we have not further explored this subject. 
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    Thirdly, since needle EMG is typically performed at low force contraction levels, 
estimates of motor unit size are biased by type I motor units. This bias is avoided with in 
situ stimulation and recording of MFCV, as both type I and type II fibres are measured. 
    Finally, the difference in sampling size may also affect diagnostic accuracy. With 
needle EMG, several sites in several muscles are investigated, whereas MFCV is 
measured in a single muscle. Our data shows that examination of MFCV, even in a 
single muscle, raises the diagnostic yield. We have not studied the value of conducting 
MFCV measurements in more than one muscle. 
    The method of measuring MFCV that we used in this study is well established.14,15,17 
Reproducibility experiments in a test-retest situation have been performed by Van der 
Hoeven, who found Pearson measurement-remeasurement coefficients of 0.88 for mean 
MFCV and 0.78 for F/S ratio.15 Furthermore, our values for normal subjects correlate well 
with those of others. Nevertheless, several drawbacks of our methodology should be 
mentioned. 
    Firstly, co-stimulation of nerve-twig endings cannot be excluded entirely. This usually 
leads to the recording of fast potentials with a slow rise time. Theoretically, it may also 
give rise to spikes with longer latencies, imitating normal or slow-conducting muscle fibre 
action potentials. To verify the origin of the action potentials, jitter can be measured. We 
have not performed such jitter measurements in our patients. 
    Secondly, the calculated conduction velocity is an estimate of the true propagation 
velocity, as the exact distance of sarcolemmal propagation of an action potential cannot 
be assessed. While the distance is measured at the surface of the muscle, the precise 
intramuscular location of the tips of both stimulating and recording electrodes is not 
certain and may vary if the electrodes are not perpendicular to the skin. This may lead to 
an error of up to 8% in MFCV.15 Furthermore, the precise course of the muscle fibre in 
the muscle is uncertain. In our experiments, the relatively long distance between 
stimulation and recording electrodes of 50 mm will minimize the effect of any skew 
deviation. 
    Finally, the size of the stimulus field may cause excitation of fibres at a distance from 
the tip of the electrode, again adding to uncertainty in estimating distance of propagation. 
However, as earlier experiments by Troni et al. showed a linear relation between 
conduction velocity and interelectrode distance, a negligible influence of the size of the 
electrical field, compared to interelectrode distance, can be assumed.14
    In conclusion, we have demonstrated that inclusion of MFCV studies, even though 
performed in a single muscle, improves the specificity and diagnostic yield of the 
electrophysiological assessment of patients with suspected inflammatory myopathy. The 
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technique is easy to use and results in quantifiable and objective data. Furthermore, we 
found a strong correlation of muscle fibre conduction velocity variability and structural 
changes in muscle tissue. 
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ABSTRACT 
 
A family with paramyotonia (PC) congenita caused by a Gly1306Val mutation in the 
voltage gated sodium channel gene SCN4A was investigated. A previous study has 
shown that exposure to cold aggravates the muscle stiffness in patients with this 
mutation. However, the mechanism behind cold sensitivity and the sodium channel 
defect remained unclear. In order to gain a better understanding of sarcolemmal 
propagation in these patients, we measured muscle-fiber conduction velocity (MFCV) 
invasively. We studied four PC patients, and four  healthy subjects at room temperature. 
After the muscle was cooled, MFCV was measured again in two PC patients and the four 
control subjects. MFCV was significantly lower in the PC patients at room temperature, 
compatible with dysfunctional sodium channels. After cooling, MFCV was significantly 
lower in both groups as compared to room temperature. The relative slowing was 1.4% 
per °C for PC patients, and 1.5% per °C  for healthy subjects. These results indicate that 
in these PC patients, mutant and wild-type sodium channels respond equally to cold 
exposure. Thus, MFCV is abnormal in these patients, but the aggravation of muscle 
stiffness can not be explained by an abnormal sarcolemmal response to cold. 
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INTRODUCTION 
 
Paramyotonia congenita (PC) is caused by a mutation in the SCN4A gene, which 
encodes for the sarcolemmal voltage-gated sodium channel. Several different mutations 
have been identified.3,21 In 1992, McClatchey et al. identified a Gly1306Val mutation in a 
family with PC with a clinical phenotype of exercise-induced muscle stiffness, aggravated 
by cold.12
    As yet, the underlying mechanism of the cold-sensitivity in these patients is unclear. In 
vitro studies of cold-exposure of normal rat muscle fibers and squid axons have shown 
three electrophysiological effects: sustained depolarization of the sarcolemmal potential,2 
delayed closure of sodium channels after depolarization,8 and increased number of 
channels remaining in a slow inactivated state.16 As a result, fewer active and closed 
sodium channels are available to generate and propagate action potentials along the 
sarcolemma, which should  result in lower muscle-fiber conduction velocity (MFCV) 
values. 
    However, mutant sodium channels that remain in a slow inactivated state cannot 
contribute to the continuous sodium influx that causes paramyotonia.9 If the number of 
active sodium channels is decreased due to cold, muscle stiffness would not be 
aggravated. Therefore, it was suggested that mutant Na+ channels respond abnormally 
to cold.7,16 To our knowledge, in vivo studies confirming this notion have not been 
performed. Since patients do not show paralysis after cold, no blocking of action 
potentials, as reported for autosomal-recessive myotonia congenita,4 was expected. 
    We studied the functionality of sodium channels in vivo by measuring propagation 
velocity along the sarcolemma. We used a needle electromyographic (EMG) technique to 
estimate MFCV1,19 of members of a family of PC patients with the Gly1306Val mutation, 
at room temperature and after cooling of the muscle. 
  
METHODS 
 
We invited four members of a Dutch family of PC patients, in whom the SCN4A gene 
(17q23-q25) missense mutation Gly1306Val had been identified, to participate. They all 
suffered from exercise-induced progressive stiffness of the neck, trunk, forearm, and 
hand, and to a lesser degree, of the calf and toe muscles. Detailed clinical characteristics 
are given in Table 1.  
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TABLE 1. Clinical characteristics of the PC patients. 
Patient 
# 
Age, 
sex 
Signs at room 
temperature 
Cold-
sensitivity 
Episodic 
weakness 
Eyelid 
paramyotonia 
Percussion 
myotonia 
1 49, f Yes Yes No Yes Yes 
2 40, f Yes Yes No Yes Yes 
3 54, f Yes but mild No No Yes No 
4 48, m Yes but mild No No Yes No 
 
 
    Laboratory investigations showed a slightly elevated serum creatine kinase level in 
three  patients. Needle EMG showed abundant myotonic discharges at room temperature 
in all four  patients. 
    Experiments were carried out after informed consent was given, and according to the 
Helsinki principles. The study was approved for by the Hospital Ethical Committee. Four 
healthy controls were included in the protocol: two men (aged 29 and 42), and two 
women (aged 27 and 29).  
 
MFCV measurements 
MFCV was measured on a Synergy EMG system (Oxford, United Kingdom) using a 
modified Troni method.1,19 In short, muscle fibers were electrically stimulated using a 
monopolar needle electrode. Propagating action potentials were recorded with a 
concentric needle electrode approximately 50 mm proximally from the stimulation site. In 
each test, mean MFCV and range of velocities were determined for at least 20 spikes. 
 
Protocol 
First, MFCV was measured in the brachioradial muscle at room temperature (skin 
temperature > 30° C). This muscle was chosen because it was easily accessible both for 
MFCV measurements and for the cooling procedure. Next, the muscle was cooled using 
ice packs, which were strapped around the forearm and elbow. This method is generally 
accepted,6 although a discrepancy between skin and intramuscular temperature of up to 
1.7° C may be present.17 Patient 3 and 4 declined to take part in the cooling. 
    During the cooling, both stimulation and recording needles were left in situ. The ice 
packs were applied for at least 15 minutes, until skin temperature had dropped to below 
18° C. Immediately hereafter, MFCV measurements were repeated.  
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TABLE 2. Results of MFCV measurements 
Subjects Temperature Mean MFCV (± SD) 
Range (min-max 
MFCV) 
Healthy 
controls 
30°C 3.9 m/s (± 0.6) 2.9 – 6.5 m/s 
Healthy 
controls 
18°C 3.2 m/s (± 0.4) 2.5 – 4.3 m/s 
Patients  
      
         
        * 
            *  
30°C 2.9 m/s (± 0.6) 1.3 – 4.3 m/s 
Patients 
       
       * 18°C 2.4 m/s (± 0.3) 1.3 – 3.1 m/s 
   * P < 0.0001 
 
 
RESULTS 
 
The results of the MFCV measurements are shown in Table 2. Mean MFCV at room 
temperature was significantly lower in the PC group than the healthy subjects. This 
slowing affected most fibers, as is shown in Figure 1. 
    After exposure to cold, mean MFCV was significantly reduced (p<0.0001) from normal 
temperature, in both the PC patients and control group. Most, if not all, fibers were 
affected by the slowing of propagation. Mean temperature effect for the PC patients was 
0.04 m/s (or 1.4%) per °C and for the controls was 0.07 m/s (or 1.5%) per °C. 
 
 
 
FIGURE 1. Histogram of conduction velocities of patients and controls at room temperature. 
A shift to lower spectrum of conduction velocities in the patients can be seen. 
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DISCUSSION 
 
This study shows that propagation of action potentials along the sarcolemma of PC 
patients with the Gly1306Val mutation is slowed at room temperature, as expected. 
Exposure to cold further reduces propagation, but to an extent relatively equal to the 
effect in healthy controls. These results suggest that mutant sodium channels respond 
normally to cold.  
 
    Using a technique that measures MFCV invasively, we were able to demonstrate that 
a mutation leading to malfunction of the sarcolemmal sodium channel slows down the 
propagation of action potentials. In general, MFCV is dependent on two important factors. 
First, MFCV is correlated to the diameter of a muscle fiber, which determines the internal 
(cytoplasmic) resistance of a fiber. In a previous study, we showed a linear relation of 
MFCV and muscle-fiber diameter in patients with neuromuscular disorders.1 Second, the 
action potential propagation depends on the generation of membrane potentials and 
therefore on the concentration of essential ions at both sides of the membrane, and the 
function of numerous ion channels, most importantly the sodium channels. Examples of 
pathology leading to abnormal conduction  have been reported in hypokalemic periodic 
paralysis22 and, using a technique with surface recordings, in myotonia congenita.4 
MFCV depends strongly on fiber diameter,1 but there is no evidence of extensive fiber 
atrophy in PC patients. More likely, the slowing at room temperature is caused by the 
abnormal functionality of the sodium channels. The Gly1306Val mutation causes a defect 
in the cytoplasmic gate of the sodium channel, which no longer closes in the late phase 
of the depolarization.12 Three main mechanisms of slowing related to this defect, can be 
identified. 
    First, mutant channels remaining open cannot contribute to action potential generation, 
and thus propagation is slowed.8,13 If the pool of excitable channels is smaller, the local 
current will be smaller as well. This may be confirmed by future experiments, using an 
adjusted arrangement of recording and filtering, to assess the rise time of individual 
spikes as a measure for the strength of the local action potential. Second, a continuous 
sodium influx,  through the mutant channels that remain open, results in sustained 
depolarization of the membrane.9,14 This will reduce the membrane potential difference 
between the region where the action potential is momentarily located and the adjacent 
region, also slowing propagation. Third, part of the role of mutant channels may be to 
modulate the action of normal channels  by altering the membrane potential via 
prolonged or repeated openings. For example, persistent depolarization reduces the pool 
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of excitable sodium channels via depolarization-induced sodium-channel slow 
inactivation. Slowed conduction velocity would result from a diminished pool of excitable 
normal channels. As such, the modulating effects of mutant channels on normal channels 
may be important to slowed MFCV, more than the possibly small contribution of mutant 
channels to the sarcolemmal sodium current.13 
 
    The relative effect of cold exposure on propagation velocity in the PC patients was 
similar to the control group, and comparable to the 0.05 m/s per °C found in amphibian 
muscle.18 This suggests that wild-type and mutant channels respond similarly to cold. 
Like wild-type channels, mutant channels will increasingly remain in a slow inactivated 
and closed state, and thus cannot contribute to an increase of paramyotonia. However, 
we have assessed sarcolemmal cold-sensitivity rather than that of individual mutant and 
wild-type sodium channels. Our data therefore cannot completely refute the existence of 
differences in temperature effects at a channel level.  
    If the impact of temperature on mutant channels is attenuated, as has been 
suggested,7,16 the mutant channel modulation of normal channels would be relatively 
constant with temperature, and the relative slowing of MFCV would be similar to that in 
healthy subjects. 
    Muscle stiffness was aggravated by cold in patients 1 and 2, in the presence of 
electrical activity. Other factors should be considered to explain this, such as altered 
propagation when entering the T-tubuli, changes in the intracellular calcium regulation, or 
a disturbance of the contractile mechanism. For example, at normal temperature, the 
effect of abnormal sodium channels on intracellular calcium via triggering of trains of 
action potentials or low-level persistent depolarization may be effectively combated by 
robust calcium reuptake mechanisms. As temperature declines, calcium reuptake may be 
suppressed while the mutant sodium current remains relatively unchallenged. 
    Interestingly, Nielsen and others have shown that the resting membrane potential 
further depolarizes with cooling,15 which was attributed to an abnormal temperature-
associated opening of mutant sodium channels.11 Moreover, in vitro research showed 
that slow inactivation at room temperature was defective in mutant sodium channels 
associated with episodic weakness.7 It therefore seems evident that the cold-sensitivity in 
sodium channelopathies associated with weakness is due to a combination of abnormal 
opening of active channels and defective slow inactivation. However, in the same study, 
slow inactivation was found to be normal in those mutations that cause myotonia without 
paresis.7 That study did not include the Gly1306Val mutation. Our patients did not exhibit 
episodic or cold-associated weakness, and slow inactivation of sodium channels seemed 
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not to be differentially affected by cold. Therefore our findings are in line with the results 
of that in vitro study. 
    Few families carrying the Gly1306Val mutation have been described.5,10,12,20 Most 
patients exhibited  exercise-induced muscle stiffness. Some patients had cold-sensitivity 
of stiffness, and none had cold- and exercise-induced muscle weakness. This is different 
from the classic PC of Eulenburg, in which patients exhibit a period of paresis or even 
paralysis, especially after performing exercise in the cold. The clinical signs of our 
patients are in line with those previously reported from the Gly1306Val mutation, 
including the heterogeneity of cold sensitivity. Noticably, Fournier et al. described 
patients with the Gly1306Val mutation and with a phenotype of myotonia permanens, 
without aggravation by cold or exercise.5 This suggests that considerable variation in 
genotype-phenotype correlation is present in this mutation. 
 
    In conclusion, MFCV is slower in PC patients with the Gly1306Val mutation than 
controls at room temperature. The additional slowing after cold exposure is similar to that 
of controls, suggesting that the clinically present cold-sensitivity of myotonia is not due to 
an abnormal response of the sarcolemma to cold. 
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ABSTRACT 
 
Mutations in the myosin heavy chain gene (MYH7) can cause several distinct phenotypes 
depending on the location of the mutation: hypertrophic cardiomyopathy (several exons), 
myosin storage myopathy (exon 37/39) or Laing distal myopathy (exon 32-36). Here, we 
describe a unique combination of hypertrophic cardiomyopathy and hypertrophic distal 
myopathy in a family with a MYH7 Val606Met mutation (exon 16). 
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INTRODUCTION 
 
Three disorders with a distinct phenotype have been linked to mutations in the myosin 
heavy chain gene (MYH7): familial hypertrophic cardiomyopathy (FHCM),1 myosin 
storage myopathy,2 and Laing-type distal myopathy.3 Patients with FHCM do not show 
symptomatic skeletal muscle weakness, and there usually is no cardiac involvement in 
myosin storage myopathy and Laing myopathy.  
    Nearly 200 different MYH7 gene mutations have been described in patients with 
FHCM, indicating significant allelic heterogeneity.1 In contrast, both myosin storage 
myopathy (exons 37/29)2 and Laing distal myopathy (exons 32-26)3 are caused by 
mutations restricted to the light meromyosin (LMM) domain.4 Here we describe a new 
combination of FHCM and a symptomatic distal myopathy with prominent hypertrophy in 
a family with a MYH7 Val6006Met mutation. 
 
CASE REPORT 
 
A 53-year-old woman presented at our outpatient clinic, complaining of pain and 
weakness of both forearms and lower legs. The symptoms gradually developed over the 
course of several years. She frequently stumbled because of a foot drop. Both pain and 
weakness worsened with motor activity. Her past medical history was significant for an 
autosomal dominant form of FHCM, caused by a Val606Met mutation in exon 16 of 
MYH7.5 For family details, see figure 1 (index patient, III-3). 
    At examination, there was weakness of the intrinsic hand musculature on both sides 
(Medical Research Counsil grade 4) with mild atrophy of the first dorsal interosseus. In 
addition, there was a bilateral paresis of the dorsiflexors of the ankle and great toe (MRC 
grade 4), with a striking hypertrophy of the tibialis anterior muscles on both sides (Figure 
2A). The remainder of the neurological examination was normal. Laboratory investigation 
showed a slight increase in creatine kinase levels (up to 400 U/l). 
    We examined three family members with the disease mutation and subclinical 
cardiological abnormalities. The son of the index patient (IV-1, 25 years of age) did not 
complain of muscle weakness, and did not show abnormalities on clinical examination. 
Patient IV-4 (male, 23 years of age) did not complain of muscle weakness either. 
Neurological examination was normal, except for a mild atrophy of the tibial muscles. 
Patient IV-7 (female, 24 years of age) had no overt muscle weakness, but stopped 
playing sports at an early age, and never volunteered during sport activities in school. At 
clinical examination there was slight hypertrophy of the tibialis anterior muscles. 
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FIGURE 1. Pedigree of the family under investigation. The arrow points to the index 
patient. All patients in whom the MYH7 mutation was confirmed suffered from a 
hypertrophic cardiomyopathy (FHCM). The black symbols represent the 4 patients with 
the MYH7 mutation who in addition showed evidence for a distal myopathy and who 
underwent neurophysiological examination. Other family members were not examined 
neurologically. 
     
 
METHODS 
 
Neurophysiological studies 
In all subjects, concentric needle EMG was performed in the forearm flexors, quadriceps 
femoris, tibialis anterior, and extensor hallucis longus, all on the right side.  
    Muscle fiber conduction velocity (MFCV) was measured invasively in three subjects, 
according to the modified Troni method as described in the introduction of the thesis.6
 
Muscle ultrasound 
Ultrasound studies in the transverse plane were performed in forearm flexors, quadriceps 
femoris and tibialis anterior muscles, using a real-time phased-array scanner with a 7.5 
MHz transducer. Per muscle, three consecutive measurements were made and the 
results were averaged. Muscle thickness was measured with electronic calipers during 
the examination,7 and compared to our database of 200 control subjects. Echo-intensity 
was determined using computer-assisted grey-scale analysis.  
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Muscle Biopsy 
In the index patient, muscle biopsies were taken from the quadriceps and the tibialis 
anterior muscle. Specimens from both muscles were frozen and cut for enzyme and 
immune histochemical stainings and for electron microscopy (EM).  
 
Genetics 
In subject III-3 and IV-7 we performed a mutation screening of the entire protein coding 
sequence of the MYH7 gene (exon 3 – 40), to screen for possible compound 
heterozygosity. 
 
RESULTS 
 
Neurophysiological studies 
The results of the ancillary investigations are summarized in Table 1. Needle EMG 
yielded clear myopathic changes (small polyphasic units) in the distal muscles of all 
subjects. Mean MFCV was slightly increased in the index patient (III-3), with an increased 
F/S ratio due to several fast conducting fibers (up to 9,0 m/s) indicating fiber 
hypertrophy.6 Patient IV-4 had a normal mean MFCV with an increased F/S ratio due to a 
few slowly conducting fibers (up to 1,9 m/s) indicating fiber atrophy.6
 
 
TABLE 1. Summary of clinical and laboratory findings 
MFCV Muscle biopsy Sub-
ject 
 
Muscle 
weak-
ness 
Myopa-
thic 
EMG 
Muscle thickness 
(US) 
mean 
(m/s)* 
F/S 
ratio** proximal distal 
III-3 + + strongly increased   
(>4 SD) 
4.6 ±1.7 3.6 normal 
 
Abnor-
mal 
IV-1 - + normal n/a n/a n/a n/a 
IV-4 - + slightly decreased   
(~2 SD) 
4.1±0.9 2.7 n/a n/a 
IV-7 +/- + normal 3.7±0.4 1.7 n/a n/a 
US, ultrasound, n/a, not available 
*: normal value: 3.6 ± 0.4   
**: normal value < 2.1 
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FIGURE 2. (A) Lower limbs of the index patient. There is extensive bilateral 
hypertrophy of the tibialis anterior muscles. (B) Muscle ultrasound showing a 
marked hypertrophy of the tibialis anterior muscles (between markers (X)). 
(C-E) Muscle biopsy from the tibialis anterior muscle. There are multiple 
fibers with internal nuclei (C: white arrows). (D and E) Muscle fibers positive 
for antibodies against slow and fast myosin, respectively. The black arrow in 
E points to a muscle fiber expressing both types of myosin. White and black 
bars represent a length of 50 micron. 
 
 
Muscle ultrasound 
Ultrasound confirmed the clinical impression of prominent tibial muscle hypertrophy in 
patient III-3 (muscle thickness > 4 SD, Figure 2B) and mild atrophy in subject IV-4. 
Despite the clinical impression of tibial muscle hypertrophy, muscle ultrasound remained 
within normal limits in subject IV-7. 
 
Muscle biopsy 
The quadriceps muscle did not show abnormalities, except for one ragged-red fiber in 
EM. However, the tibialis anterior muscle revealed too many internal nuclei (in 17% of 
fibers, normally 3%, Figure 2C), some single degenerating fibers and too many 
hypertrophic fibers (25 % of the muscle fibers exceeded a diameter of 70 and 85 micron 
in type I and II fibers respectively). Immune stainings for dystrophin, alpha-sarcoglycan, 
merosin, dysferlin, caveolin-3, and HLA-ABC were normal. Muscle fibers were positive 
for either slow or fast myosin, but 3 % of the fibers showed expression of both myosin 
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types (Figure 2D and E). EM occasionally revealed lipofuscine (mostly without a clear fat 
component), some mitochondria with paracrystalline inclusions, and Z-line streaming. 
 
Genetics 
No additional mutations in the MYH7 gene were found, excluding compound 
heterozygosity as a cause of the described phenotype. 
 
DISCUSSION 
 
The phenotype caused by mutations in MYH7 is heterogeneous, and depends on the 
location of the allelic mutation. Mutations throughout the gene can cause FHCM, while 
those causing myosin storage myopathy and Laing’s type myopathy are exclusively 
localized in the LMM region.8,9 Although subtle EMG and muscle biopsy changes have 
been described in FHCM mutations,10,11 these have not been reported to cause skeletal 
muscle weakness. Here, we present a FHCM patient with a MYH7 mutation outside the 
LMM region who nevertheless developed a symptomatic distal myopathy. Moreover, 
three family members showed myopathic changes on EMG examination. Finally, we 
excluded compound heterozygosity, confirming the relation between the Val606Met 
mutation and the myopathic phenotype. 
 
     Intriguingly, the neuromuscular phenotype of the Val606Met mutation clearly differed 
from the two other myopathies caused by MYH7 mutations. In patients with myosin 
storage myopathy, the distribution of weakness is either scapuloperoneal or 
scapulopelvic. Although there is a prominent involvement of the tibialis anterior muscles 
in Laing’s myopathy, atrophy is a hallmark of this disorder. In contrast, our index patient 
developed a striking hypertrophy of the distal muscles, which was confirmed by muscle 
ultrasound. Furthermore, the macroscopic findings corroborated with MFCV 
measurements (showing fast conducting fibers). Finally, patients with Laing’s myopathy 
usually present symptoms before 30 years of age,11 whereas in our patient symptoms 
started around the fifth decade.  
    The distal myopathies in general are a heterogeneous group of disorders, including 
diseases like Laing, Udd, Miyoshi, Welander and Nonaka myopathy. To allow proper 
differentiation it is essential to consider age at onset, upper or lower limb predominance, 
involvement of the anterior or posterior compartment of the leg and mode of inheritance. 
The distal myopathy we describe here has a unique combination of features: late onset, 
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lower limb involvement of the anterior compartment and an autosomal dominant 
inheritance.  
    Hemodynamic dysfunction precedes the histopathology of hypertrophic 
cardiomyopathy in patients with FHCM, implying that the hypertrophic phenotype may be 
a compensatory response to sarcomere mutations.12 This is further supported by the 
observation that many genes are upregulated in the hearts of cardiomyopathy patients, 
including those producing secondary hypertrophy.13 A similar compensatory mechanism 
might underlie the skeletal muscle hypertrophy in our ptient: while the 4th generation 
subjects (aged in their twenties) had EMG evidence of a distal myopathy, marked 
hypertrophy was only found in the 53-year-old index patient.  
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Summary 
 
 
This thesis aims to contribute to the understanding of the propagation velocity of action 
potentials along the outer membrane of human muscle fibres. Furthermore, it shows the 
clinical applicability of measurements of this propagation velocity, estimated as MFCV, in 
patients with neuromuscular disorders.  
 
    The introduction served as a background for the intricate physiological principles of the 
generation and propagation of action potentials. 
    Next, the development of a technique to measure MFCV was discussed. Muscle fibres 
can be stimulated directly, using a needle and a surface electrode. Muscle fibre action 
potentials can be evoked by inducing a small current, which depolarises the membrane 
locally. The potentials are propagated, and recorded with a needle electrode, inserted 
approximately 50 mm away from the stimulation site. Conduction velocity is calculated 
using the latencies of the recorded spikes, and the estimated distance between 
stimulation and recording electrodes. This technique has been validated by other authors 
in the past. The modified Troni method, as it was baptised after the inventing author, was 
consistently used in this thesis. 
    Two main questions were asked: what are physiological determinants of MFCV, and 
can the technique be applied in the diagnosis of neuromuscular disorders? 
 
PHYSIOLOGICAL DETERMINANTS OF MUSCLE FIBRE CONDUCTION VELOCITY 
 
Fibre diameter is the main determinant of MFCV. A linear relation was demonstrated in 
muscles fibres of the frog in vitro  by Håkansson in 1962, and assumed to be present in 
human muscle fibres as well. In chapter 2, we demonstrated that this assumption was 
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valid, even in patients with various neuromuscular disorders. The formula MFCV (m/s) = 
0.043 * diameter (µm) + 0.83 can be used to express MFCV in human muscle fibres. 
    Atrophy of muscle fibers is a clear sign of pathology, but does not specifically  points to 
an underlying cause. Muscle fibre atrophy can be due to degeneration (as in myopathies) 
and denervation (as in neurogenic disorders). Small fibres may also be due to 
regeneration (as in myopathies and neurogenic disorders). We have not found a specific 
pattern of abnormal MFCV for either myopathic or neurogenic fibre diameter pathology. 
    Similarly, muscle fibre hypertrophy can be a sign of myopathy, as well as of a 
neurogenic disorder. Fibres can be swollen due to intracellular pathology, due to 
regeneration, or prior to fibre splitting. Moreover, fibre hypertrophy can result from 
extensive training. 
    Thus, invasive MFCV estimation predicts the distribution of fibre diameters with high 
confidence, even in patients with a neuromuscular disorder. 
 
    The second important determinant of MFCV is the functional ability of the sarcolemmal 
ion channels to generate action potentials. It is almost impossible to perform in vivo 
experiments on specific ion channels in healthy subjects. However, measurements made 
in patients in whom specific ion channel defects are known, preferably by genetic testing, 
can elucidate some of the complex electrochemical mechanisms. 
    In chapter 9, we demonstrated that MFCV is slowed down significantly in patients with 
a defect of the inner gate of the sodium channel. The slowing can be explained by a 
lesser amount of proper sodium channels being available for action potential generation, 
and by the effects of sustained depolarisation of the membrane resting potential. This 
study illustrates that the assessment of MFCV can be regarded as an 
electrophysiological bridge, connecting the gene mutation and its resulting molecular 
defect on one hand, and the clinical signs and symptoms on the other hand. 
 
    Temperature has an effect on virtually all neurophysiologic processes. Physiological 
kinetics tend to slow down after cooling. For example, the speed with which ion channels 
open and close is slowed, whereby closing is more affected than opening. The effect of 
delayed closure of Na+ channels following depolarisation is that less channels will be in 
the right functional state (closed and active) for action potential generation, and a 
prolonged Na+ influx will result in a sustained depolarisation of the sarcolemma. We have 
measured a mean temperature effect of 1.4% slowing of MFCV per °C in healthy 
subjects (chapter 9). Interestingly, the relative effect was similar in patients with a sodium 
channel defect, although these patients suffered from an increase in exercise-induced 
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cramps when exposed to cold. Presumably, mutant and wildtype channels responded in 
a similar way to cold exposure, and other factors should be taken into consideration to 
explain the cold-induced signs. 
 
    The duration of the interval between two subsequent stimuli also determines MFCV. 
This behaviour is described by the VRF curve, which shows that over a time period of 
1000 ms following a discharge, fibres subsequently enter a state of inexcitability, 
subnormal MFCV, and supernormal MFCV. The underlying mechanisms of the VRF 
remain partly unknown. Our experiments with direct muscle fibre stimulation at high 
frequencies revealed that the stimulus frequency effects were strong in fast fibres,  but 
appeared to be absent in slow conducting fibres (chapter 3). We suggested that this VRF 
difference may be related to differences in intracellular Ca2+ concentration, as the rate of 
release and reuptake of Ca2+ differs between type I and type II fibres. 
    In chapter 4, we have demonstrated that single fibre EMG can yield abnormal results 
due to the effect of the VRF, if F-waves interfere with the train of stimuli. Considering the 
fact that single fibre EMG is regarded upon as a definite diagnostic examination in 
patients suspected of myasthenia gravis, the importance of recognising falsely abnormal 
measurements is obvious. 
 
CLINICAL APPLICATIONS 
 
First, a brief overview of qualitative and quantitative EMG techniques was given. For a 
new technique to be introduced, a comparison with the ‘gold standards’ must be made. 
 
    In chapter 6, we assessed the diagnostic yield of MFCV studies in myopathies. 
Measurements were obtained from 125 patients with signs and symptoms suggestive of 
a myopathy. The study was carried out according to the principles of the STARD 
guideline. These include a prospective nature of inclusion, independency of the 
technique and the diagnostic process, and independency of the study-examiner and the 
patient’s clinician. 
    We found a high sensitivity and specificity of MFCV studies. In metabolic and non-
dystrophic myopathies, and in channelopathies, a single MFCV measurement performed 
superior to qualitative needle EMG of multiple muscles. Turns-amplitude analysis 
performed worse than EMG and MFCV. Our results suggest that MFCV can be used as a 
quantitative EMG technique in the diagnosis of myopathies, especially in metabolic and 
non-dystrophic myopathies, and channelopathies. 
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    Chapter 7 introduced MFCV as a tool for early diagnosis of ALS. The solid relation 
between MFCV and fibre diameter was used to search for fibres with abnormal 
diameters, which can be an early sign of motor neuron degradation. We obtained MFCV 
from muscles that showed no atrophy or loss of force, nor electromyographical 
abnormalities, that would indicate anterior horn disease. Muscle biopsies were obtained, 
to verify the neurogenic cause of abnormal MFCV. We included 18 patients in whom a 
diagnosis of ALS was suspected, but could not be proven, according to established 
research criteria. After a mean follow-up period of 16 months, 9 patients developed ALS. 
Sensitivity of abnormal MFCV for developing ALS was 89%. In other words, abnormal 
MFCV, due to abnormal fibre diameters, often could be demonstrated even before 
anterior horn disease became evident by clinical or electromyographical signs in the 
affected region. 
 
    In chapter 8, a group of patients with signs and symptoms suggestive of an 
inflammatory myopathy  was prospectively examined with EMG and MFCV. Needle EMG 
is known to be sensitive in these patients, but false positive findings are quite common. 
We found similar sensitivity and specificity of EMG and MFCV. By combining EMG and 
MFCV results, we were able to raise specificity from 33% to 67%. These results 
demonstrated that EMG and MFCV can be complementary examinations in 
electrodiagnosis. 
 
    Chapter 10 illustrated the utility of the solid relation between MFCV and fibre diameter 
in hypertrophic fibres. A family with a new phenotype of a mutation in the myosin heavy 
chain gene was examined. These patients suffered from a unique combination of 
hypertrophic cardiomyopathy and hypertrophic distal myopathy. We measured MFCV of 
the anterior tibial muscle in 3 family members. Our results were in concordance with the 
findings of muscle ultrasound examination, and muscle biopsy: high MFCV in the 
hypertrophic muscle, low MFCV in the smaller muscle, and normal MFCV in the normal 
muscle. 
 
    Some important advantages of MFCV over conventional nEMG examination can be 
identified.  
    Firstly, a MFCV measurement is made independent of voluntary contraction. It is 
therefore much more a random sample of muscle fibres. It is not affected by the 
recruitment order of motor units, and fibres from any motor unit type can be assessed. 
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Also, fibres that do not belong to a motor unit but are still excitable, for example in 
denervation, can be measured. In contrast, nEMG can only assess those fibres that can 
be voluntarily activated, unless spontaneous fibre discharges are present. 
    Secondly, both stimulating and recording needle electrodes are close to the active 
fibres. The spatial factor, a source of variability of a MUP, is relatively small, because 
distances are fixed during a measurement.  
    Thirdly, MFCV measurement is a quantitative EMG technique. The method is well 
defined, which should minimise variation due to the performance of the examiner, and 
due to subjective interpretation of the measurements. Furthermore, objective numerical 
results are generated, and cut-off values for normal and abnormal are clearly defined. 
    Finally, cooperation of the patient during the test is not a necessity. Muscles that can 
not be activated voluntarily, can still be measured, for example in critical illness 
myopathy. 
    Of course, nEMG can be done more quickly, and in almost any muscle. Furthermore, 
nEMG can solidly distinct myopathic from neurogenic pathology. In contrast, abnormal 
MFCV is a reflection of abnormal fibre diameters only. We did not find any characteristics 
of abnormal MFCV that specifically pointed to a neurogenic or myopathic underlying 
disorder. 
 
    In conclusion, we identified several important determinants of MFCV in human muscle 
fibres in vivo. Furthermore, we showed that MFCV studies can be a viable 
electrodiagnostic tool in neuromuscular disorders. The solid relationship between fibre 
diameter and MFCV, and the need for functional ion channels for propagation, are the 
strong foundations of the diagnostic utility of MFCV studies. 
 
TECHNICAL CONSIDERATIONS 
 
Measurements of MFCV are easy to perform and do not require any special equipment. 
In total, we have measured MFCV in 173 patients and 39 healthy volunteers. We were 
unable to obtain reliable recordings in 7 patients (3%), which is an acceptable number of 
failed studies. The reasons for failure were: stimulation of nerve twigs that could not be 
avoided, especially in the quadriceps muscle (see below); examination was too painful; 
not able to position the recording electrode close enough to the stimulated fibres in order 
to record sharp spikes. In most patients and control subjects however, recordings were 
obtained quickly and without problems. The estimate of the average time needed to 
11. summary 150 
complete a study of 20 or more muscle fibres, is 15 minutes. Hereafter, 5 more minutes 
are needed to evaluate the measurements and calculate the results. 
    The biceps brachii muscle proved easier to study than the quadriceps muscle due to 
two reasons. First, concomitant nerve twig stimulation was a problem that occurred more 
frequently in the lateral and medial vastus muscle. Second, it was sometimes difficult to 
find the stimulated bundle of fibers 50 mm away from the site of stimulation. In the biceps 
brachii, fibers run parallel to the length of the muscle, nicely aligned. In contrast, fibers 
from the medial and lateral vastus muscle run in different angles, and from superficial to 
deep into the muscle. 
    We have also examined the anterior tibial muscle (3 patients), the gastrocnemius 
muscle (3 patients), and the brachioradial muscle (4 patients and 4 controls). Normal 
values of mean MFCV of muscles, other than the biceps brachii and quadriceps muscle, 
have been reported before for the deltoid muscle, brachioradial muscle, gastrocnemius 
muscle, and tibialis anterior muscle. These measurements, together with ours, 
demonstrate that the modified Troni technique can be applied to many muscles. 
    As said before, stimulation of nerve twigs close to the stimulating electrode can 
interfere with the measurements. It can produce false results, because the estimated 
distance of propagation along the muscle fibre becomes unreliable. Furthermore, it can 
cause gross muscle twitching, displacing the needles. The issue of nerve twig stimulation 
has been addressed by Troni in his original contribution. He suggested that nerve twig 
stimulation gave rise to a blunt-shaped complex, usually preceding the spikes evoked by 
direct muscle fibre stimulation, and accompanied by a visible contraction. During our 
measurements, the contraction was typically of such magnitude that it suggested 
stimulation of not one, but multiple nerve twigs. This may be due to antidromic excitation 
of nerve twigs connected to the twig that was stimulated, or direct stimulation of  multiple 
nerve twigs simultaneously. In most instances, nerve twig stimulation could be avoided 
when the stimulation electrode was replaced, or the stimulation current was reduced.  
    As suggested by Stålberg, measurement of muscle fibre ‘jitter’ can be used to verify 
the origin of the evoked response. Jitter is the measure of the small variation in latency of 
two subsequent discharges. Jitter is due to random variation in various conditions, such 
as intracellular and extracellular ion concentrations, the number of ion channels 
available, and the size of the action potential. Muscle fibre jitter can be measured by 
stimulating muscle fibres with a train of stimuli, and measuring the interval between each 
set of two subsequent responses. Muscle fibre jitter should not exceed 10 μs. In contrast, 
stimulation of nerve twigs would yield a higher jitter, usually about 15-30 μs. The 
difference is caused by the neuromuscular transmission, which is less stable. 
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    We have performed jitter measurements of muscle fibres. Usually, jitter did not exceed 
10 μs (data not published). Measurements tended to be complicated however. A 
stimulation rate at a high frequency would be preferred, similar to 10 or 20 Hz which is 
used to measure jitter of the neuromuscular junction, in patients suspected of myasthenia 
gravis. However, both stimulation and recording needles tend to move during stimulation, 
due to the contraction of the muscle fibre. This movement induces jitter as well, because 
the distance between the action potential and the tip of the needle changes. The 
movement induced by stimulation at higher frequencies can be quite severe. Moreover, 
the effect of the VRF induces yet another source of jitter. 
    A stimulation rate at a low frequency, for example of 1 or 3 Hz, can be used to prevent 
heavy contraction, as well as the VRF effect. However, a measurement requires 50 
sequential stimulations and recordings, in order to reliably estimate jitter. At 1 Hz 
stimulation, the examiner then needs to keep both needles in place for 50 seconds. A 
small displacement of the needle, due to an unstable hand of the examiner, again 
induces artificial jitter. 
    These concerns have prevented us from implementing muscle fibre jitter 
measurements at a routine base. 
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Samenvatting 
 
 
Dit proefschrift heeft een bijdrage geleverd aan de kennis over de geleidingssnelheid van 
een actiepotentiaal over het membraan van een spiervezel. Tevens is de toepassing van 
metingen van spiervezelgeleidingssnelheid (muscle fibre conduction velocity, MFCV) als 
klinisch neurofysiologische methode in de diagnostiek van patiënten met een 
neuromusculaire ziekte verhelderd. 
 
    In de introductie werd fysiologische achtergrond gegeven van het ontstaan van, en de 
voortgeleiding van actiepotentialen. 
    Hierna werd de ontwikkeling van de techniek om MFCV mee te meten geschetst. Deze 
techniek maakt gebruikt van naaldelektroden, waarmee stroom aan de spiervezel wordt 
gegeven, en op die manier een actiepotentiaal wordt opgewekt. Met een tweede 
naaldelektrode, die ongeveer 50 mm verderop in de spier wordt ingebracht, kan deze 
voortgeleide potentiaal worden gemeten. Door de afstand tussen de twee naalden te 
delen door de tijd die tussen de stimulatie en de meting van de potentiaal is verlopen, 
verkrijgt men de MFCV. Deze techniek is door andere auteurs ontwikkeld en gevalideerd. 
Hij wordt de ‘gemodificeerde Troni methode’ genoemd. Deze techniek is in dit proefschrift 
gebruikt voor alle experimenten. 
    Twee vraagstellingen werden onderzocht: wat zijn de fysiologische determinanten van 
MFCV, en kan deze techniek worden gebruikt in de diagnostiek van neuromusculaire 
aandoeningen? 
 
DETERMINANTEN VAN SPIERVEZELGELEIDINGSSNELHEID 
 
De belangrijkste determinant van MFCV is de diameter van de spiervezel. Al in 1962  
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werd een lineaire relatie tussen spiervezeldiameter en geleidingssnelheid aangetoond in 
spiervezels van kikkers, en men nam aan dat deze relatie ook in mensen van toepassing 
was. Onze experimenten, beschreven in hoofdstuk 2, hebben dit bevestigd. Zelfs in 
patiënten met een neuromusculaire aandoening bleek een lineaire relatie aanwezig. 
Deze kan beschreven worden met de formule: snelheid (m/s) = 0.043* diameter (µm) + 
0.83. 
    Atrofie en hypertrofie van spiervezels is een duidelijk teken van pathologie, zonder dat 
dit specifiek naar de onderliggende oorzaak wijst. Atrofie kan worden veroorzaakt door 
degeneratie (zoals in een myopathie), denervatie (zoals in een neurogene 
aandoeningen), en ook regeneratie kan kleine vezeldiameters geven. We hebben geen 
specifiek patroon van abnormale MFCV gevonden passend bij een myopathie of een 
neurogene aandoening. 
    Ook spiervezelhypertrofie kan passen bij zowel een myopathische als een neurogene 
aandoening. Vezels kunnen zwellen als gevolg van intracellulaire pathologie, als gevolg 
van regeneratie, of als voorbode van vezelsplijting. Ook training kan vezelhypertrofie 
geven, al gaat dit niet gepaard met andere afwijkingen in de spier, zoals vezelatrofie. 
    Onze studie laat zien dat een MFCV meting een goede voorspeller is van de distributie 
van vezeldiameters, zelfs in patiënten met een neuromusculaire aandoening. 
 
    De tweede belangrijke determinant van MFCV is de functionaliteit van de ionkanalen in 
de membraan, nodig om actiepotentialen op te kunnen wekken. Het is bijna niet mogelijk 
om specifieke ionkanalen te meten in gezonde mensen in vivo. Wel kunnen we patiënten 
meten met een bekende ionkanaal-aandoeningen, bij voorkeur aangetoond door een 
DNA test, en op die manier de functie van dat kanaal herleiden. 
    In hoofdstuk 9 beschrijven we de vertraging van MFCV in patiënten met een 
natriumkanaal aandoening. In deze aandoening sluit de binnenste poort van het kanaal 
niet, waardoor het kanaal disfunctioneel wordt. De vertraging kan worden verklaard door 
het kleinere aantal functionele natriumkanalen dat beschikbaar is, en door de continue 
inwaartse stroom van natrium door de defecte kanalen, leidend tot langdurige 
depolarisatie van de rustpotentiaal. Onze studie laat zien dat metingen van MFCV een  
neurofysiologische brug vormen tussen het genetische en moleculaire defect enerzijds, 
en de symptomen van de patiënt anderzijds. 
 
    Temperatuur heeft invloed op vrijwel alle neurofysiologische processen. In het 
algemeen worden deze trager als het kouder wordt. Zo neemt de snelheid waarmee 
ionkanalen in de membraan open en dicht gaan af in de kou, waarbij het sluiten meer 
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wordt beïnvloedt dan het openen. Het resultaat hiervan is dat, in koude, natriumkanalen 
na depolarisatie niet snel genoeg sluiten. Hierdoor zijn er minder kanalen beschikbaar 
voor de volgende actiepotentiaal, en blijft natrium de spiervezel instromen, met 
langdurige depolarisatie van de membraanpotentiaal tot gevolg. Wij hebben een 
temperatuurseffect van 1.4% vertraging van MFCV per °C gemeten in gezonde 
proefpersonen (hoofdstuk 9). Dit effect was hetzelfde in patiënten met een natriumkanaal 
defect, die echter wel klachten van spierstijfheid bij inspanning kregen door de koude. 
Het mechanisme hierachter lijkt dus niet direct gerelateerd aan een abnormale reactie 
van de kanalen op koude (hoofdstuk 9). 
  
    MFCV van een actiepotentiaal wordt ook beïnvloedt door het tijdsinterval met de vorige 
actiepotentiaal. Dit wordt beschreven door de snelheidsherstel curve (VRF), die laat zien 
dat na een ontlading eerst een korte refractaire periode volgt, waarna een periode van 
supernormale MFCV, waarbij de snelheid tot 115% van normaal kan oplopen. Deze 
normaliseert weer over een periode van 1000 ms. Het onderliggende mechanisme van 
de VRF is onbekend. In onze experimenten, beschreven in hoofdstuk 3, met 
vezelstimulaties met verschillende tijdsintervallen tussen de stimulaties, kwam een 
verschil naar voren in het gedrag van snelle en langzame vezels. Supernormale MFCV 
trad op in de snelle vezels, die tot 120% versnelden, maar niet in de trage vezels. We 
suggereerden dat de VRF gerelateerd kan zijn aan de intracellulaire calcium 
concentratie, omdat deze verschilt in type I and type II spiervezels. 
    In hoofdstuk 4 hebben we laten zien dat het VRF effect andere neurofysiologische 
metingen nadelig kan beïnvloeden, namelijk single fibre elektromyografie (EMG). We 
toonden aan dat F-golven, optredend tijdens de stimulatie treintjes, tot abnormale 
resultaten leiden. Dit is van belang, omdat single fibre EMG een belangrijk diagnostisch 
onderzoek is in patiënten die worden verdacht van een stoornis in de neuromusculaire 
overgang. 
 
KLINISCHE TOEPASSING VAN METINGEN VAN SPIERVEZELGELEIDINGS-
SNELHEID 
 
Eerst werd een kort overzicht gegeven van de kwalitatieve en kwantitatieve naald EMG 
technieken (hoofdstuk 5). Deze context is nodig, omdat de toepasbaarheid van een 
nieuwe techniek altijd moet worden vergeleken met een gouden standaard.  
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    In hoofdstuk 6 hebben we de diagnostische opbrengst van MFCV metingen in 
patiënten met een myopathie beschreven. De metingen waren prospectief verricht in een 
niet-geselecteerde groep van 125 patiënten met klachten en symptomen van een 
spierziekte. De studie was opgezet volgens het STARD initiatief, welke onder andere 
inhoudt een prospectieve opzet, onafhankelijkheid van metingen en het diagnostische 
proces, en onafhankelijkheid van de onderzoeker en de behandelend arts. 
    Sensitiviteit en specificiteit van MFCV was hoog. In metabole en niet-dystrofische 
myopathiën, en in kanaalziekten, bleek een MFCV meting in één spier een hogere 
diagnostische opbrengst te hebben dan de referentietechnieken, te weten kwalitatieve en 
kwantitatieve EMG van meerdere spieren, en het spierbiopt. Onze resultaten laten zien 
dat voor de neurofysiologische diagnostiek van bepaalde spierziekten, MFCV meting de 
voorkeur mag hebben boven conventioneel EMG. 
 
    In hoofdstuk 7 hebben we een andere toepassing van MFCV beschreven: vroege 
opsporing van amyotrofische lateraal sclerose (ALS). Omdat MFCV nauw gerelateerd is 
aan spiervezeldiameter, en afwijkende spiervezeldiameters een eerste teken kan zijn van 
degeneratie van voorhoorn cellen, zoals bij ALS, hebben we onderzocht of afwijkende 
MFCV een vroeg teken kan zijn van ALS. We hebben metingen gedaan bij patiënten bij 
wie de diagnose ALS werd vermoedt, maar niet kon worden gesteld aan de hand van 
bestaande criteria. De metingen werden verricht in spieren die zowel klinisch als in het 
naald EMG geen afwijkingen vertoonden, wijzend op een neuromusculaire aandoening. 
Van deze spier werd ook een spierbiopt verkregen. 18 patiënten werden geïncludeerd, 
waarvan de helft ALS ontwikkelde, na een gemiddelde follow-up duur van 16 maanden. 
Sensitiviteit van MFCV voor het ontwikkelen van ALS was 89%. Met andere woorden, we 
konden abnormale MFCV aantonen in spieren die pas op een later tijdstip klinische en 
elektromyografische tekenen van voorhoornlijden lieten zien.  
 
    Hoofdstuk 8 beschrijft een prospectieve studie naar de diagnostische waarde van 
MFCV en EMG bij patiënten met klachten en symptomen van een inflammatoire 
myopathie. We vonden een gelijke sensitiviteit en specificiteit van EMG en MFCV. 
Echter, door de resultaten van beide onderzoeken te combineren konden de we 
specificiteit omhoog brengen van 33% naar 67%. Dit onderzoek laat zien dat de klinisch 
neurofysiologische diagnostiek verbeterd kan worden door het combineren van 
verschillende onderzoeken, zoals EMG en MFCV. 
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    In hoofdstuk 10 werd nog een voorbeeld gegeven van de kracht van de relatie tussen 
spiervezel diameter en MFCV, maar nu aan de bovenkant van het spectrum. Een familie 
met een nieuw fenotype van een mutatie in de zware keten van myosine werd 
beschreven. Deze patiënten hadden een combinatie van een hypertrofische 
cardiomyopathie en een hypertrofische distale myopathie. MFCV werd gemeten in de 
tibialis anterior van 3 patienten. De resultaten kwamen overeen met de bevindingen van 
het spierbiopt en de spierecho: hoge MFCV in de hypertrofische spier, lage MFCV in de 
atrofe spier, en normale MFCV in de normale spier. 
 
    Enkele belangrijke verschillen tussen MFCV en conventioneel naald EMG onderzoek 
kunnen worden genoemd. 
    Ten eerste wordt MFCV gemeten onafhankelijk van willekeurig aanspannen, in 
tegenstelling tot naald EMG. Dit betekent dat een min of meer ‘random sample’ 
spiervezels van type I en type II wordt gemeten, onafhankelijk van de recrutering van 
motor units, die volgens een vaste volgorde geschiedt.  Daarnaast is de meting niet 
afhankelijk van de medewerking van de patiënt. Bovendien kunnen spiervezels gemeten 
worden die niet meer tot motor units behoren, zoals gedenerveerde spiervezels. 
    Ten tweede is de meetfout, die gerelateerd is aan de positie van de naald ten opzichte 
van de actieve spiervezels, kleiner in MFCV metingen dan in EMG. Dit komt omdat zowel 
de stimulatie- als de meetelektrodes vlakbij de spiervezels worden geplaatst, en niet 
meer van positie veranderen tijdens een meting. 
    Ten derde is MFCV een kwantitatieve methode, die weinig ruimte laat voor subjectieve 
beoordeling. De uitslag wordt gegeven in getallen, in plaats van een niet-normatieve 
classificatie, en grenzen tussen normaal en abnormaal zijn duidelijk gesteld. 
    Aan de andere kant kan naald EMG onderzoek snel worden verricht, en is bijna iedere 
spier in het menselijke lichaam toegankelijk voor de naaldelektrode. Bovendien kan men 
met naald EMG heel goed een onderscheidt maken tussen een myopathie en een 
neurogene aandoening. Dit is met MFCV vooralsnog niet mogelijk.  
 
    Concluderend kunnen we stellen dat dit proefschrift heeft laten zien dat de 
belangrijkste determinant van MFCV de spiervezeldiameter is. Daarnaast zijn functionele 
ionkanalen van belang. Deze twee factoren vormen de solide basis waarop de 
toepasbaarheid van MFCV als klinisch neurofysiologische methode is gestoeld.  
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LIST OF ABBREVIATIONS USED THROUGHOUT THIS THESIS 
 
ALS, amyotrophic lateral sclerosis  
EMG, electromyography 
F/S ratio, ratio of fastest to slowest fiber conduction velocity 
IPI, interpotential interval 
LMN, lower motor neuron  
MFCV, muscle fibre conduction velocity 
MFD, muscle fibre diameter 
MUAP, motor unit action potential 
MUP, motor unit potential 
nEMG, needle electromyography 
PC, paramyotonia congenita 
SD, standard deviation 
SFEMG, single fibre electromyography 
TAA, turns-amplitude analysis 
UMN,upper motor neuron 
VRF, velocity recovery function 
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